Year |
Citation |
Score |
2024 |
Gesmundo I, Pedrolli F, Cai R, Sha W, Schally AV, Granata R. Growth hormone-releasing hormone and cancer. Reviews in Endocrine & Metabolic Disorders. PMID 39422787 DOI: 10.1007/s11154-024-09919-4 |
0.302 |
|
2021 |
Gesmundo I, Granato G, Fuentes-Fayos AC, Alvarez CV, Dieguez C, Zatelli MC, Congiusta N, Banfi D, Prencipe N, Leone S, Brunetti L, Castaño JP, Luque RM, Cai R, Sha W, ... ... Schally AV, et al. Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling. Cancers. 13. PMID 34439107 DOI: 10.3390/cancers13163950 |
0.321 |
|
2020 |
Barabutis N, Akhter MS, Uddin MA, Kubra KT, Schally AV. GHRH Antagonists Protect Against Hydrogen Peroxide-Induced Breakdown of Brain Microvascular Endothelium Integrity. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 52: 336-339. PMID 32403147 DOI: 10.1055/a-1149-9347 |
0.341 |
|
2020 |
Recinella L, Chiavaroli A, Orlando G, Ferrante C, Marconi GD, Gesmundo I, Granata R, Cai R, Sha W, Schally AV, Brunetti L, Leone S. Publisher Correction: Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice. Scientific Reports. 10: 4850. PMID 32161298 DOI: 10.1038/s41598-020-61185-x |
0.313 |
|
2019 |
Uddin MA, Akhter MS, Singh SS, Kubra KT, Schally AV, Jois S, Barabutis N. GHRH antagonists support lung endothelial barrier function. Tissue Barriers. 1669989. PMID 31578921 DOI: 10.1080/21688370.2019.1669989 |
0.311 |
|
2019 |
Zhang C, Cai R, Lazerson A, Delcroix G, Wangpaichitr M, Mirsaeidi M, Griswold AJ, Schally AV, Jackson RM. Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin. Lung. PMID 31392398 DOI: 10.1007/s00408-019-00257-w |
0.339 |
|
2019 |
Villanova T, Gesmundo I, Audrito V, Vitale N, Silvagno F, Musuraca C, Righi L, Libener R, Riganti C, Bironzo P, Deaglio S, Papotti M, Cai R, Sha W, Ghigo E, ... Schally AV, et al. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proceedings of the National Academy of Sciences of the United States of America. PMID 30659154 DOI: 10.1073/pnas.1818865116 |
0.304 |
|
2018 |
Schally AV, Wang H, He J, Cai R, Sha W, Popovics P, Perez R, Vidaurre I, Zhang X. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH. Proceedings of the National Academy of Sciences of the United States of America. PMID 30373845 DOI: 10.1073/Pnas.1813375115 |
0.316 |
|
2018 |
Qin YJ, Chu WK, Huang L, Ng CHY, Chan TCY, Cao D, Yang C, Zhang L, Huang SP, Li J, Lin HL, Li WQ, Chen L, Schally AV, Chan SO, et al. Induction of Apoptosis in Pterygium Cells by Antagonists of Growth Hormone-Releasing Hormone Receptors. Investigative Ophthalmology & Visual Science. 59: 5060-5066. PMID 30357400 DOI: 10.1167/iovs.18-24751 |
0.335 |
|
2018 |
Oláh G, Dobos N, Vámosi G, Szabó Z, Sipos É, Fodor K, Harda K, Schally AV, Halmos G. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152). European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 123: 371-376. PMID 30076951 DOI: 10.1016/j.ejps.2018.08.002 |
0.364 |
|
2018 |
Cui T, Schally AV. Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1. Oncotarget. 9: 28745-28756. PMID 29983893 DOI: 10.18632/oncotarget.25676 |
0.387 |
|
2018 |
Muñoz-Moreno L, Schally AV, Prieto JC, Carmena MJ, Bajo AM. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer. The Prostate. PMID 29748961 DOI: 10.1002/pros.23648 |
0.3 |
|
2018 |
Jimenez JJ, DelCanto GM, Popovics P, Perez A, Vila Granda A, Vidaurre I, Cai RZ, Rick FG, Swords RT, Schally AV. A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone. British Journal of Haematology. PMID 29663325 DOI: 10.1111/bjh.15207 |
0.323 |
|
2018 |
Shen J, Zhang N, Lin YN, Xiang P, Liu XB, Shan PF, Hu XY, Zhu W, Tang YL, Webster KA, Cai RZ, Schally A, Wang J, Yu H. Regulation of Vascular Calcification by Growth Hormone-Releasing Hormone and its Agonists. Circulation Research. PMID 29618597 DOI: 10.1161/CIRCRESAHA.117.312418 |
0.306 |
|
2018 |
Sipos E, Dobos N, Rozsa D, Fodor K, Olah G, Szabo Z, Szekvolgyi L, Schally AV, Halmos G. Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines. Oncotargets and Therapy. 11: 933-941. PMID 29503568 DOI: 10.2147/OTT.S148174 |
0.336 |
|
2017 |
Pópulo H, Nunes B, Sampaio C, Batista R, Pinto MT, Gaspar TB, Miranda-Alves L, Cai RZ, Zhang XY, Schally AV, Sobrinho-Simões M, Soares P. Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer. Hormones & Cancer. PMID 28924876 DOI: 10.1007/S12672-017-0307-4 |
0.324 |
|
2017 |
Moscona JC, Peters MN, Schally AV, Srivastav S, Delafontaine P, Irimpen A. The effects of a growth hormone-releasing hormone antagonist and a gastrin-releasing peptide antagonist on intimal hyperplasia of the carotid artery after balloon injury in a diabetic rat model☆ Artery Research. 19: 56. DOI: 10.1016/J.ARTRES.2017.06.006 |
0.342 |
|
2016 |
Deivaraju C, Temple HT, Block N, Robinson P, Schally AV. LHRH receptor expression in sarcomas of bone and soft tissue. Hormone Molecular Biology and Clinical Investigation. PMID 27639272 DOI: 10.1515/hmbci-2016-0001 |
0.304 |
|
2016 |
Romero MJ, Lucas R, Dou H, Sridhar S, Czikora I, Mosieri EM, Rick FG, Block NL, Sridhar S, Fulton D, Weintraub NL, Bagi Z, Schally AV. Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America. PMID 26831066 DOI: 10.1073/Pnas.1525520113 |
0.346 |
|
2015 |
Schally AV, Perez R, Block NL, Rick FG. Potentiating effects of GHRH analogs on the response to chemotherapy. Cell Cycle (Georgetown, Tex.). 14: 699-704. PMID 25648497 DOI: 10.1080/15384101.2015.1010893 |
0.369 |
|
2015 |
Rick FG, Schally AV. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. Urologic Oncology. 33: 270-274. PMID 25512159 DOI: 10.1016/j.urolonc.2014.11.006 |
0.35 |
|
2015 |
Engel JB, Tinneberg HR, Block NL, Berkes E, Schally AV. Analogs of luteinizing Hormone-Releasing hormone in the treatment of endometriosis Journal of Endometriosis. 7: 19-26. DOI: 10.5301/je.5000208 |
0.386 |
|
2014 |
Popovics P, Schally AV, Szalontay L, Block NL, Rick FG. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels. Oncotarget. 5: 4567-78. PMID 24994120 |
0.308 |
|
2014 |
Jaszberenyi M, Rick FG, Popovics P, Block NL, Zarandi M, Cai RZ, Vidaurre I, Szalontay L, Jayakumar AR, Schally AV. Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists. Proceedings of the National Academy of Sciences of the United States of America. 111: 781-6. PMID 24379381 DOI: 10.1073/pnas.1322622111 |
0.316 |
|
2014 |
Maxuitenko Y, Block N, Schally A, Reich S, Goldstein P. 330 Preclinical development of BIS-1602, first in class growth hormone releasing hormone antagonist European Journal of Cancer. 50: 107. DOI: 10.1016/S0959-8049(14)70456-3 |
0.373 |
|
2013 |
Rick FG, Block NL, Schally AV. Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert Opinion On Pharmacotherapy. 14: 2237-47. PMID 23984804 DOI: 10.1517/14656566.2013.834328 |
0.305 |
|
2013 |
Florea V, Majid S, Kanashiro–Takeuchi R, Block N, Schally A, Hare J, Rodrigues C. CYTOPROTECTIVE EFFECT OF GROWTH HORMONE RELEASING HORMONE AGONIST IN CARDIAC STEM CELLS Journal of the American College of Cardiology. 61: E1820. DOI: 10.1016/S0735-1097(13)61820-3 |
0.311 |
|
2013 |
Moscona J, Khan Z, Schally AV, Delafontaine P, Irimpen A. THE EFFECTS OF A GROWTH HORMONE-RELEASING HORMONE ANTAGONIST AND A GASTRIN-RELEASING PEPTIDE ANTAGONIST ON INTIMAL HYPERPLASIA OF THE CAROTID ARTERY AFTER BALLOON INJURY IN A DIABETIC RAT MODEL Journal of the American College of Cardiology. 61: E1178. DOI: 10.1016/S0735-1097(13)61178-X |
0.448 |
|
2013 |
Rick F, Abi-Chaker A, Szalontay L, Perez R, Block N, Halmos G, Schally A. 1600 COMBINATION OF BOMBESIN/GASTRIN-RELEASING PEPTIDE ANTAGONIST WITH GROWTH-HORMONE-RELEASING HORMONE ANTAGONIST AUGMENTS SHRINKAGE OF BENIGN PROSTATIC HYPERPLASIA IN RATS Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.3150 |
0.369 |
|
2012 |
Buchholz S, Seitz S, Engel JB, Montero A, Ortmann O, Perez R, Block NL, Schally AV. Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH). Hormone Molecular Biology and Clinical Investigation. 9: 87-94. PMID 25961354 DOI: 10.1515/Hmbci-2011-0002 |
0.328 |
|
2012 |
Laimou D, Katsila T, Matsoukas J, Schally A, Gkountelias K, Liapakis G, Tamvakopoulos C, Tselios T. Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: Enhanced enzymatic stability and biological properties European Journal of Medicinal Chemistry. 58: 237-247. PMID 23127987 DOI: 10.1016/j.ejmech.2012.09.043 |
0.347 |
|
2012 |
Szalontay L, Benveniste RJ, Schally AV, Vidaurre I, Nadji M, Zarandi M, Block NL, Kovacs M. Inhibitory effects of GHRH antagonists on human GH-secreting adenoma tissue. Neuroendocrinology. 96: 81-8. PMID 22377963 DOI: 10.1159/000335989 |
0.367 |
|
2012 |
Rick FG, Szalontay L, Schally AV, Block NL, Nadji M, Szepeshazi K, Vidaurre I, Zarandi M, Kovacs M, Rekasi Z. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. The Journal of Urology. 187: 1498-504. PMID 22341819 DOI: 10.1016/j.juro.2011.11.081 |
0.334 |
|
2012 |
Pelletier G, Leclerc R, Dube D, Arimura A, Schally AV. Immunohistochemical localization of luteinizing hormone-releasing hormone (LH-RH) and somatostatin in the organum vasculosum of the lamina terminalis of the rat. Neuroscience Letters. 4: 27-31. PMID 19604915 DOI: 10.1016/0304-3940(77)90119-7 |
0.469 |
|
2012 |
Ludwig B, Rotem A, Schmid J, Steffen A, Ludwig S, Barkai U, Schally AV, Bornstein SR. New Avenue in Islet Transplantation by Macroencapsulation and Islet Pre-Treatment with Growth Hormone Releasing Hormone Agonist Transplantation Journal. 94: 713. DOI: 10.1097/00007890-201211271-01400 |
0.304 |
|
2012 |
Rick F, Seitz S, Szalontay L, Block N, Zarandi M, Hohla F, Buchholz S, Schally A. 787 GROWTH HORMONE-RELEASING HORMONE ANTAGONIST INHIBITS GROWTH OF PC-3 HUMAN PROSTATE CANCER BY INACTIVATION OF ERK AND AKT Journal of Urology. 187. DOI: 10.1016/j.juro.2012.02.875 |
0.303 |
|
2011 |
Schmid J, Ludwig B, Schally AV, Steffen A, Ziegler CG, Block NL, Koutmani Y, Brendel MD, Karalis KP, Simeonovic CJ, Licinio J, Ehrhart-Bornstein M, Bornstein SR. Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11beta-hydroxysteroid dehydrogenase. Proceedings of the National Academy of Sciences of the United States of America. 108: 13722-7. PMID 21825133 DOI: 10.1073/pnas.1110965108 |
0.354 |
|
2011 |
Kiaris H, Chatzistamou I, Papavassiliou AG, Schally AV. Growth hormone-releasing hormone: not only a neurohormone. Trends in Endocrinology and Metabolism: Tem. 22: 311-7. PMID 21530304 DOI: 10.1016/j.tem.2011.03.006 |
0.37 |
|
2011 |
Kiaris H, Block NL, Papavassiliou AG, Schally AV. GHRH and wound healing. Communicative & Integrative Biology. 4: 82-3. PMID 21509187 DOI: 10.4161/cib.4.1.14002 |
0.36 |
|
2010 |
Barabutis N, Schally AV. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle (Georgetown, Tex.). 9: 4110-6. PMID 20962577 DOI: 10.4161/cc.9.20.13787 |
0.35 |
|
2010 |
Kovács M, Schally AV, Hohla F, Rick FG, Pozsgai E, Szalontay L, Varga JL, Zarándi M. A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides. 31: 1839-46. PMID 20633588 DOI: 10.1016/j.peptides.2010.07.006 |
0.327 |
|
2010 |
Barabutis N, Siejka A, Schally AV. Effects of growth hormone-releasing hormone and its agonistic and antagonistic analogs in cancer and non-cancerous cell lines. International Journal of Oncology. 36: 1285-9. PMID 20372804 DOI: 10.3892/ijo-00000613 |
0.338 |
|
2010 |
Siejka A, Schally AV, Block NL, Barabutis N. Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. The Prostate. 70: 1087-93. PMID 20232355 DOI: 10.1002/pros.21142 |
0.329 |
|
2010 |
Siejka A, Schally AV, Barabutis N. Activation of Janus kinase/signal transducer and activator of transcription 3 pathway by growth hormone-releasing hormone. Cellular and Molecular Life Sciences : Cmls. 67: 959-64. PMID 20012909 DOI: 10.1007/s00018-009-0224-y |
0.307 |
|
2010 |
Buchholz S, Weber F, Schally A, Ortmann O, Seitz S. Combination of antagonists of growth hormone-releasing hormone antagonist (GHRH) with rapamycin as a potential therapy in human breast cancers. Journal of Clinical Oncology. 28: e13627-e13627. DOI: 10.1200/JCO.2010.28.15_SUPPL.E13627 |
0.317 |
|
2010 |
Abdel-Wahab M, Schally A, Rick F, Szalontay L, Varga J, Shi Y, Zarandi M, Pollack A. Antagonists of growth hormone-releasing hormone potentiate radiation response in prostate cancer. Journal of Clinical Oncology. 28: 10597-10597. DOI: 10.1200/JCO.2010.28.15_SUPPL.10597 |
0.306 |
|
2010 |
Schally AV, Block NL. Luteinizing hormone-releasing hormone and its agonistic, antagonistic, and targeted cytotoxic analogs in prostate cancer Drug Management of Prostate Cancer. 27-39. DOI: 10.1007/978-1-60327-829-4_2 |
0.324 |
|
2009 |
Emons G, Sindermann H, Engel J, Schally AV, Gründker C. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology. 90: 15-8. PMID 19521066 DOI: 10.1159/000225410 |
0.316 |
|
2009 |
Schwarzstein L, Aparicio NJ, Turner D, Turner EA, Schally AV, Coy DH. Pituitary and testicular response to LH-RH and to a long-acting analogue (D-leu-6-LH-RH-ethylamide). Andrologia. 10: 59-65. PMID 343641 DOI: 10.1111/J.1439-0272.1978.Tb01316.X |
0.422 |
|
2009 |
Buchholz S, Schally A, Krishan A, Papadia A, Ortmann O, Seitz S. Combination of a novel growth hormone releasing hormone Antagonist JMR 132 and Tamoxifen enhances the inhibitory effects on growth of ZR 75 and T47D estrogen dependent human breast cancer cells in vitro and in vivo Geburtshilfe Und Frauenheilkunde. 69. DOI: 10.1055/s-0029-1225201 |
0.328 |
|
2009 |
Seitz S, Schally A, Papadia A, Rick F, Szlatonay L, Ortmann O, Engel J, Köster F, Buchholz S. 0141 Combination of antagonists of growth hormone-releasing hormone with docetaxel as potential therapy in breast cancer in a preclinical study The Breast. 18: S54. DOI: 10.1016/S0960-9776(09)70172-9 |
0.309 |
|
2008 |
Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Mã©Tabolisme. 40: 315-22. PMID 18491250 DOI: 10.1055/s-2008-1073142 |
0.356 |
|
2008 |
Kovács M, Schally AV, Varga JL, Zarándi M. Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists. Current Medicinal Chemistry. 15: 314-21. PMID 18288987 DOI: 10.2174/092986708783497355 |
0.329 |
|
2008 |
Chatzistamou I, Volakaki AA, Schally AV, Kiaris H, Kittas C. Expression of growth hormone-releasing hormone receptor splice variant 1 in primary human melanomas. Regulatory Peptides. 147: 33-6. PMID 18255167 DOI: 10.1016/j.regpep.2007.12.008 |
0.323 |
|
2008 |
Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nature Clinical Practice. Endocrinology & Metabolism. 4: 33-43. PMID 18084344 DOI: 10.1038/Ncpendmet0677 |
0.405 |
|
2008 |
Engel J, Rozsa B, Schally AV, Dezso B, Toth G, Flasko T, Block NL, Nadji M, Halmos G. LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) RECEPTORS IN BPH AS POTENTIAL MOLECULAR TARGETS FOR THERAPY WITH CETRORELIX Journal of Urology. 179: 449-450. DOI: 10.1016/S0022-5347(08)61318-X |
0.311 |
|
2007 |
Schally AV. Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art. Bju International. 100: 2-4. PMID 17594347 DOI: 10.1111/j.1464-410X.2007.06942.x |
0.328 |
|
2007 |
Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nature Clinical Practice. Endocrinology & Metabolism. 3: 157-67. PMID 17237842 DOI: 10.1038/ncpendmet0399 |
0.325 |
|
2006 |
Schally AV, González Bárcena D. [History of clinical studies on hypothalamic hormone analogs in Mexico]. Gaceta Mã©Dica De Mã©Xico. 142: 315-25. PMID 17022307 |
0.363 |
|
2006 |
Halmos G, Schally AV, Bernardino AL, Varga JL. Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas. International Journal of Oncology. 29: 463-9. PMID 16820890 DOI: 10.3892/Ijo.29.2.463 |
0.398 |
|
2006 |
Buchholz S, Keller G, Schally AV, Halmos G, Hohla F, Heinrich E, Koester F, Baker B, Engel JB. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proceedings of the National Academy of Sciences of the United States of America. 103: 10403-7. PMID 16801542 DOI: 10.1073/Pnas.0602971103 |
0.398 |
|
2006 |
Zarandi M, Varga JL, Schally AV, Horvath JE, Toller GL, Kovacs M, Letsch M, Groot K, Armatis P, Halmos G. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proceedings of the National Academy of Sciences of the United States of America. 103: 4610-5. PMID 16537407 DOI: 10.1073/pnas.0511348103 |
0.371 |
|
2006 |
Schally AV, Varga JL. Antagonists of growth hormone-releasing hormone in oncology. Combinatorial Chemistry & High Throughput Screening. 9: 163-70. PMID 16533148 DOI: 10.2174/138620706776055449 |
0.451 |
|
2006 |
Stangelberger A, Schally AV, Nagy A, Szepeshazi K, Kanashiro CA, Halmos G. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207. The Prostate. 66: 200-10. PMID 16173040 DOI: 10.1002/Pros.20335 |
0.39 |
|
2006 |
Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G, Kanashiro CA, Corey E, Vessella R. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. International Journal of Cancer. Journal International Du Cancer. 118: 222-9. PMID 16003723 DOI: 10.1002/Ijc.21292 |
0.334 |
|
2006 |
Varga JL, Schally AV. Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Cancer Handbook of Biologically Active Peptides. 483-489. DOI: 10.1016/B978-012369442-3/50073-8 |
0.38 |
|
2006 |
Schally AV, Engel J. Analogs of Luteinizing Hormone-Releasing Hormone (lhrh) in Cancer Handbook of Biologically Active Peptides. 421-427. DOI: 10.1016/B978-012369442-3/50063-5 |
0.383 |
|
2005 |
Fintini D, Alba M, Schally AV, Bowers CY, Parlow AF, Salvatori R. Effects of combined long-term treatment with a growth hormone-releasing hormone analogue and a growth hormone secretagogue in the growth hormone-releasing hormone knock out mouse. Neuroendocrinology. 82: 198-207. PMID 16601359 DOI: 10.1159/000092520 |
0.468 |
|
2005 |
Engel JB, Schally AV, Halmos G, Baker B, Nagy A, Keller G. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocrine-Related Cancer. 12: 999-1009. PMID 16322338 DOI: 10.1677/Erc.1.01022 |
0.303 |
|
2005 |
Schally AV. [The discovery of hypothalamic hormones and the development of antitumor analogs]. Annales D'Urologie. 39: S46-50. PMID 16302710 DOI: 10.1016/S0003-4401(05)80007-5 |
0.388 |
|
2005 |
Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, Szepeshazi K, Köster F, Kovitz K, Groot K, Zarandi M, Kanashiro CA. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proceedings of the National Academy of Sciences of the United States of America. 102: 17424-9. PMID 16299104 DOI: 10.1073/Pnas.0506844102 |
0.338 |
|
2005 |
Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, Hammann BD, Armatis P, Kanashiro CA. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. European Journal of Cancer (Oxford, England : 1990). 41: 2735-44. PMID 16291086 DOI: 10.1016/J.Ejca.2005.08.022 |
0.392 |
|
2005 |
Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G, Engel JB. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. European Journal of Cancer (Oxford, England : 1990). 41: 2196-202. PMID 16182122 DOI: 10.1016/J.Ejca.2005.06.018 |
0.358 |
|
2005 |
Szepeshazi K, Schally AV, Nagy A, Halmos G. Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. Pancreas. 31: 275-82. PMID 16163060 DOI: 10.1097/01.Mpa.0000175892.97036.A7 |
0.338 |
|
2005 |
Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G, Engel JB. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5549-57. PMID 16061872 DOI: 10.1158/1078-0432.Ccr-04-2464 |
0.399 |
|
2005 |
Kanashiro CA, Schally AV, Varga JL, Hammann B, Halmos G, Zarandi M. Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma. Cancer Letters. 226: 123-31. PMID 16039952 DOI: 10.1016/J.Canlet.2005.01.008 |
0.437 |
|
2005 |
Nagy A, Schally AV. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biology of Reproduction. 73: 851-9. PMID 16033997 DOI: 10.1095/Biolreprod.105.043489 |
0.375 |
|
2005 |
Keller G, Schally AV, Groot K, Toller GL, Havt A, Köster F, Armatis P, Halmos G, Zarandi M, Varga JL, Engel JB. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 102: 10628-33. PMID 16027368 DOI: 10.1073/Pnas.0504102102 |
0.402 |
|
2005 |
Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Westphal G, Halmos G, Engel JB. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue. Cancer Research. 65: 5857-63. PMID 15994963 DOI: 10.1158/0008-5472.Can-04-3816 |
0.396 |
|
2005 |
Kanashiro CA, Schally AV, Nagy A, Halmos G. Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms. International Journal of Oncology. 27: 169-74. PMID 15942657 DOI: 10.3892/Ijo.27.1.169 |
0.307 |
|
2005 |
Müller EE, Arimura A, Sawano S, Saito T, Schally AV. Growth hormone-releasing activity in the hypothalamus and plasma of rats subjected to stress. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 125: 874-8. PMID 15938289 DOI: 10.3181/00379727-125-32228 |
0.462 |
|
2005 |
Heuser M, Schlott T, Schally AV, Kahler E, Schliephake R, Laabs SO, Hemmerlein B. Expression of gastrin releasing Peptide receptor in renal cell carcinomas: a potential function for the regulation of neoangiogenesis and microvascular perfusion. The Journal of Urology. 173: 2154-9. PMID 15879878 DOI: 10.1097/01.Ju.0000158135.26893.Bc |
0.343 |
|
2005 |
Nagy A, Schally AV. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Current Pharmaceutical Design. 11: 1167-80. PMID 15853664 |
0.343 |
|
2005 |
Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. Fertility and Sterility. 83: 1125-33. PMID 15831285 DOI: 10.1016/J.Fertnstert.2004.10.042 |
0.375 |
|
2005 |
Engel JB, Keller G, Schally AV, Halmos G, Hammann B, Nagy A. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2408-15. PMID 15788692 DOI: 10.1158/1078-0432.Ccr-04-1670 |
0.356 |
|
2005 |
Engel JB, Keller G, Schally AV, Toller GL, Groot K, Havt A, Armatis P, Zarandi M, Varga JL, Halmos G. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. The Journal of Clinical Endocrinology and Metabolism. 90: 3614-21. PMID 15784701 DOI: 10.1210/Jc.2004-2179 |
0.349 |
|
2005 |
Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. The Prostate. 64: 303-15. PMID 15754342 DOI: 10.1002/Pros.20262 |
0.399 |
|
2005 |
Rekasi Z, Czompoly T, Schally AV, Boldizsar F, Varga JL, Zarandi M, Berki T, Horvath RA, Nemeth P. Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway. Proceedings of the National Academy of Sciences of the United States of America. 102: 3435-40. PMID 15728367 DOI: 10.1073/Pnas.0410006102 |
0.323 |
|
2005 |
Kiaris H, Schally AV, Kalofoutis A. Extrapituitary effects of the growth hormone-releasing hormone. Vitamins and Hormones. 70: 1-24. PMID 15727800 DOI: 10.1016/S0083-6729(05)70001-7 |
0.371 |
|
2005 |
Chatzistamou I, Kondi-Pafiti A, Politi E, Koutselini H, Schally AV. Detection of growth hormone-releasing hormone in cytologic specimens of primary breast carcinoma. Acta Cytologica. 49: 108-9. PMID 15717766 DOI: 10.1159/000326107 |
0.408 |
|
2005 |
Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P, Halmos G. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 49-57. PMID 15671527 |
0.341 |
|
2005 |
Kanashiro CA, Schally AV, Cai RZ, Halmos G. Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma. Anti-Cancer Drugs. 16: 159-65. PMID 15655413 DOI: 10.1097/00001813-200502000-00007 |
0.355 |
|
2005 |
Keller G, Engel JB, Schally AV, Nagy A, Hammann B, Halmos G. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. International Journal of Cancer. Journal International Du Cancer. 114: 831-5. PMID 15609311 DOI: 10.1002/Ijc.20806 |
0.317 |
|
2005 |
Alba M, Schally AV, Salvatori R. Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog. Endocrinology. 146: 1506-13. PMID 15564325 DOI: 10.1210/En.2004-1044 |
0.425 |
|
2004 |
Günthert AR, Gründker C, Bongertz T, Nagy A, Schally AV, Emons G. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system. Breast Cancer Research and Treatment. 87: 255-64. PMID 15528968 DOI: 10.1007/S10549-004-8806-8 |
0.399 |
|
2004 |
Günthert AR, Gründker C, Bongertz T, Schlott T, Nagy A, Schally AV, Emons G. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. American Journal of Obstetrics and Gynecology. 191: 1164-72. PMID 15507937 DOI: 10.1016/j.ajog.2004.04.020 |
0.302 |
|
2004 |
Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling. International Journal of Cancer. Journal International Du Cancer. 112: 570-6. PMID 15382037 DOI: 10.1002/Ijc.20437 |
0.371 |
|
2004 |
Chatzistamou I, Schally AV, Kiaris H, Politi E, Varga J, Kanellis G, Kalofoutis A, Pafiti A, Koutselini H. Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers. European Journal of Endocrinology / European Federation of Endocrine Societies. 151: 391-6. PMID 15362970 DOI: 10.1530/Eje.0.1510391 |
0.343 |
|
2004 |
Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends in Endocrinology and Metabolism: Tem. 15: 300-10. PMID 15350601 DOI: 10.1016/J.Tem.2004.07.002 |
0.389 |
|
2004 |
Horvath JE, Toller GL, Schally AV, Bajo AM, Groot K. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Proceedings of the National Academy of Sciences of the United States of America. 101: 4996-5001. PMID 15044692 DOI: 10.1073/pnas.0400605101 |
0.322 |
|
2004 |
Collado B, Carmena MJ, Cortés J, Schally AV, Prieto JC. Luteinizing hormone-releasing hormone antagonist Cetrorelix regulates the expression of Galphas and Galphai protein subunits and adenylate cyclase activity in rat ovary, breast and pituitary. International Journal of Oncology. 24: 725-30. PMID 14767559 |
0.339 |
|
2004 |
Varga JL, Schally AV, Horvath JE, Kovacs M, Halmos G, Groot K, Toller GL, Rekasi Z, Zarandi M. Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10. Proceedings of the National Academy of Sciences of the United States of America. 101: 1708-13. PMID 14755056 DOI: 10.1073/Pnas.0307288101 |
0.492 |
|
2004 |
Letsch M, Schally AV, Stangelberger A, Groot K, Varga JL. Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers. European Journal of Cancer (Oxford, England : 1990). 40: 436-44. PMID 14746863 DOI: 10.1016/J.Ejca.2003.10.010 |
0.434 |
|
2004 |
Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238. The Journal of Urology. 171: 911-5. PMID 14713852 DOI: 10.1097/01.Ju.0000105101.77884.06 |
0.306 |
|
2004 |
Bajo AM, Schally AV, Groot K, Szepeshazi K. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. British Journal of Cancer. 90: 245-52. PMID 14710236 DOI: 10.1038/Sj.Bjc.6601404 |
0.325 |
|
2003 |
Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proceedings of the National Academy of Sciences of the United States of America. 100: 15836-41. PMID 14660794 DOI: 10.1073/Pnas.2536558100 |
0.403 |
|
2003 |
Szepeshazi K, Schally AV, Nagy A, Wagner BW, Bajo AM, Halmos G. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer. 98: 1401-10. PMID 14508826 DOI: 10.1002/Cncr.11649 |
0.306 |
|
2003 |
Bajo AM, Schally AV, Halmos G, Nagy A. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3742-8. PMID 14506166 |
0.32 |
|
2003 |
Kiaris H, Koutsilieris M, Kalofoutis A, Schally AV. Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists. Expert Opinion On Investigational Drugs. 12: 1385-94. PMID 12882623 DOI: 10.1517/13543784.12.8.1385 |
0.371 |
|
2003 |
Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga JL, Koutselini H, Kalofoutis A. Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proceedings of the National Academy of Sciences of the United States of America. 100: 9512-7. PMID 12867592 DOI: 10.1073/Pnas.1533185100 |
0.388 |
|
2003 |
Halmos G, Schally AV, Comaru-Schally AM, Nagy A, Irimpen A. Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium. Life Sciences. 72: 2669-74. PMID 12672512 DOI: 10.1016/S0024-3205(03)00181-4 |
0.354 |
|
2003 |
Garcia-Fernandez MO, Schally AV, Varga JL, Groot K, Busto R. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Research and Treatment. 77: 15-26. PMID 12602901 DOI: 10.1023/A:1021196504944 |
0.38 |
|
2003 |
Letsch M, Schally AV, Busto R, Bajo AM, Varga JL. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proceedings of the National Academy of Sciences of the United States of America. 100: 1250-5. PMID 12538852 DOI: 10.1073/Pnas.0337496100 |
0.37 |
|
2002 |
Krebs LJ, Wang X, Nagy A, Schally AV, Prasad PN, Liebow C. Bombesin and epidermal growth factor potentiate the effect of cytotoxic LH-RH analog AN-152 in vitro. International Journal of Oncology. 21: 1325-9. PMID 12429984 DOI: 10.3892/Ijo.21.6.1325 |
0.306 |
|
2002 |
Kovacs M, Schally AV, Lee EJ, Busto R, Armatis P, Groot K, Varga JL. Inhibitory effects of antagonistic analogs of GHRH on GH3 pituitary cells overexpressing the human GHRH receptor. The Journal of Endocrinology. 175: 425-34. PMID 12429040 DOI: 10.1677/Joe.0.1750425 |
0.351 |
|
2002 |
Horvath JE, Bajo AM, Schally AV, Kovacs M, Herbert F, Groot K. Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats. Proceedings of the National Academy of Sciences of the United States of America. 99: 15048-53. PMID 12409615 DOI: 10.1073/Pnas.232579499 |
0.381 |
|
2002 |
Arencibia JM, Bajo AM, Schally AV, Krupa M, Chatzistamou I, Nagy A. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anti-Cancer Drugs. 13: 949-56. PMID 12394258 DOI: 10.1097/00001813-200210000-00007 |
0.44 |
|
2002 |
Halmos G, Schally AV, Czompoly T, Krupa M, Varga JL, Rekasi Z. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. The Journal of Clinical Endocrinology and Metabolism. 87: 4707-14. PMID 12364462 DOI: 10.1210/Jc.2002-020347 |
0.328 |
|
2002 |
Krebs LJ, Wang X, Nagy A, Schally AV, Prasad PN, Liebow C. A conjugate of doxorubicin and an analog of Luteinizing Hormone-Releasing Hormone shows increased efficacy against oral and laryngeal cancers. Oral Oncology. 38: 657-663. PMID 12353491 DOI: 10.1016/S1368-8375(01)00130-0 |
0.447 |
|
2002 |
Gründker C, Völker P, Griesinger F, Ramaswamy A, Nagy A, Schally AV, Emons G. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. American Journal of Obstetrics and Gynecology. 187: 528-37. PMID 12237622 |
0.409 |
|
2002 |
Chatzistamou I, Schally AV, Pafiti A, Kiaris H, Koutselini H. Expression of growth hormone-releasing hormone in human primary endometrial carcinomas. European Journal of Endocrinology / European Federation of Endocrine Societies. 147: 381-6. PMID 12213676 |
0.386 |
|
2002 |
Busto R, Schally AV, Varga JL, Garcia-Fernandez MO, Groot K, Armatis P, Szepeshazi K. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proceedings of the National Academy of Sciences of the United States of America. 99: 11866-71. PMID 12186980 DOI: 10.1073/Pnas.182433099 |
0.365 |
|
2002 |
Tang X, Yano T, Osuga Y, Matsumi H, Yano N, Xu J, Wada O, Koga K, Kugu K, Tsutsumi O, Schally AV, Taketani Y. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. The Journal of Clinical Endocrinology and Metabolism. 87: 3721-7. PMID 12161501 DOI: 10.1210/Jcem.87.8.8726 |
0.391 |
|
2002 |
Plonowski A, Schally AV, Busto R, Krupa M, Varga JL, Halmos G. Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers. Peptides. 23: 1127-33. PMID 12126741 DOI: 10.1016/S0196-9781(02)00043-8 |
0.326 |
|
2002 |
Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. The Prostate. 52: 173-82. PMID 12111694 DOI: 10.1002/Pros.10105 |
0.395 |
|
2002 |
Huang YT, Hwang JJ, Lee LT, Liebow C, Lee PP, Ke FC, Lo TB, Schally AV, Lee MT. Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma A431 cells. International Journal of Cancer. Journal International Du Cancer. 99: 505-13. PMID 11992539 DOI: 10.1002/Ijc.10373 |
0.338 |
|
2002 |
Szereday Z, Schally AV, Nagy A, Plonowski A, Bajo AM, Halmos G, Szepeshazi K, Groot K. Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215. British Journal of Cancer. 86: 1322-7. PMID 11953892 DOI: 10.1038/Sj.Bjc.6600235 |
0.375 |
|
2002 |
Plonowski A, Varga JL, Schally AV, Krupa M, Groot K, Halmos G. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. International Journal of Cancer. Journal International Du Cancer. 98: 624-9. PMID 11920625 DOI: 10.1002/Ijc.10221 |
0.421 |
|
2002 |
Kovacs M, Schally AV, Csernus B, Busto R, Rekasi Z, Nagy A. Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH. Journal of Neuroendocrinology. 14: 5-13. PMID 11903807 DOI: 10.1046/J.0007-1331.2001.00728.X |
0.483 |
|
2002 |
Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, Szepeshazi K. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proceedings of the National Academy of Sciences of the United States of America. 99: 3836-41. PMID 11891317 DOI: 10.1073/Pnas.052715299 |
0.336 |
|
2002 |
Schally AV, Gual C. [Anthology of the first clinical studies with hypothalamic hormones: a story of successful international cooperation]. Gaceta Mã©Dica De Mã©Xico. 138: 89-100. PMID 11885134 |
0.379 |
|
2002 |
Halmos G, Schally AV. Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix. Proceedings of the National Academy of Sciences of the United States of America. 99: 961-5. PMID 11805337 DOI: 10.1073/Pnas.012598399 |
0.471 |
|
2002 |
Kiaris H, Schally AV, Busto R, Halmos G, Artavanis-Tsakonas S, Varga JL. Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proceedings of the National Academy of Sciences of the United States of America. 99: 196-200. PMID 11773624 DOI: 10.1073/Pnas.012590999 |
0.389 |
|
2002 |
Nagy A, Schally A. Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH): A new approach to targeted chemotherapy Drugs of the Future. 27: 359. DOI: 10.1358/Dof.2002.027.04.666175 |
0.453 |
|
2002 |
Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV. Structure of the porcine LH-and FSH-releasing Hormone.: I. The proposed amino acid sequence0110 0 The Journal of Urology. 167: 1011-1014. DOI: 10.1016/S0022-5347(02)80326-3 |
0.429 |
|
2001 |
Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Bajo AM. Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. Journal of Cancer Research and Clinical Oncology. 127: 645-52. PMID 11710593 |
0.313 |
|
2001 |
Chatzistamou I, Schally AV, Varga JL, Groot K, Busto R, Armatis P, Halmos G. Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anti-Cancer Drugs. 12: 761-8. PMID 11593058 DOI: 10.1097/00001813-200110000-00008 |
0.425 |
|
2001 |
Kovacs M, Schally AV. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats. Proceedings of the National Academy of Sciences of the United States of America. 98: 12197-202. PMID 11593037 DOI: 10.1073/pnas.211442598 |
0.379 |
|
2001 |
Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G. Hypothalamic hormones and cancer. Frontiers in Neuroendocrinology. 22: 248-91. PMID 11587553 DOI: 10.1006/Frne.2001.0217 |
0.457 |
|
2001 |
Szepeshazi K, Schally AV, Armatis P, Groot K, Hebert F, Feil A, Varga JL, Halmos G. Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology. 142: 4371-8. PMID 11564700 DOI: 10.1210/Endo.142.10.8426 |
0.377 |
|
2001 |
Rekasi Z, Schally AV, Plonowski A, Czompoly T, Csernus B, Varga JL. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. The Prostate. 48: 188-99. PMID 11494334 DOI: 10.1002/Pros.1097 |
0.414 |
|
2001 |
Chatzistamou I, Schally AV, Szepeshazi K, Groot K, Hebert F, Arencibia JM. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. Cancer Letters. 171: 37-45. PMID 11485826 DOI: 10.1016/S0304-3835(01)00543-2 |
0.465 |
|
2001 |
Rekasi Z, Varga JL, Schally AV, Plonowski A, Halmos G, Csernus B, Armatis P, Groot K. Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways. Peptides. 22: 879-86. PMID 11390017 DOI: 10.1016/S0196-9781(01)00413-2 |
0.422 |
|
2001 |
Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Busto R, Halmos G. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. The Journal of Clinical Endocrinology and Metabolism. 86: 2144-52. PMID 11344219 DOI: 10.1210/Jcem.86.5.7487 |
0.403 |
|
2001 |
Kovacs M, Schally AV, Csernus B, Rekasi Z. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH. Proceedings of the National Academy of Sciences of the United States of America. 98: 1829-34. PMID 11172036 DOI: 10.1073/Pnas.98.4.1829 |
0.471 |
|
2001 |
Kiaris H, Schally AV, Armatis P. Direct action of growth hormone-releasing hormone agonist JI-38 on normal human fibroblasts: evidence from studies on cell proliferation and c-myc proto-oncogene expression. Regulatory Peptides. 96: 119-24. PMID 11111017 DOI: 10.1016/S0167-0115(00)00166-X |
0.419 |
|
2001 |
Schally AV, Gual C. Some Recollections of Early Clinical Studies on Hypothalamic Hormones: A Tale of a Successful International Collaboration The Endocrinologist. 11: 341-349. DOI: 10.1097/00019616-200109000-00001 |
0.354 |
|
2000 |
Yano T, Radulovic S, Osuga Y, Kugu K, Yoshikawa H, Taketani Y, Schally AV. Inhibition of human epithelial ovarian cancer cell growth in vitro by somatostatin analog RC-160. Oncology. 59: 45-9. PMID 11096356 DOI: 10.1159/000055287 |
0.326 |
|
2000 |
Kiaris H, Schally AV, Varga JL. Suppression of tumor growth by growth hormone-releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin-like growth factor II in H-69 small cell lung carcinoma. Cancer Letters. 161: 149-55. PMID 11090963 DOI: 10.1016/S0304-3835(00)00580-2 |
0.385 |
|
2000 |
Chatzistamou L, Schally AV, Nagy A, Armatis P, Szepeshazi K, Halmos G. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 4158-65. PMID 11051271 |
0.317 |
|
2000 |
Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z. Peptide analogs in the therapy of prostate cancer. The Prostate. 45: 158-66. PMID 11027415 DOI: 10.1002/1097-0045(20001001)45:2<158::Aid-Pros10>3.0.Co;2-K |
0.337 |
|
2000 |
Reissmann T, Schally AV, Bouchard P, Riethmiiller H, Engel J. The LHRH antagonist cetrorelix: a review. Human Reproduction Update. 6: 322-31. PMID 10972520 DOI: 10.1093/Humupd/6.4.322 |
0.386 |
|
2000 |
Schally AV. Use of GnRH in preference to LH-RH terminology in scientific papers. Human Reproduction (Oxford, England). 15: 2059-61. PMID 10967015 DOI: 10.1093/Humrep/15.9.2059 |
0.353 |
|
2000 |
Halmos G, Schally AV, Varga JL, Plonowski A, Rekasi Z, Czompoly T. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 97: 10555-60. PMID 10962030 DOI: 10.1073/Pnas.180313097 |
0.371 |
|
2000 |
Kiaris H, Schally AV, Varga JL. Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia (New York, N.Y.). 2: 242-50. PMID 10935510 DOI: 10.1038/Sj.Neo.7900074 |
0.403 |
|
2000 |
Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A, Esteve JP, Pour PM, Schally AV, Vaysse N, Susini C, Buscail L. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proceedings of the National Academy of Sciences of the United States of America. 97: 9180-5. PMID 10900262 DOI: 10.1073/Pnas.130196697 |
0.316 |
|
2000 |
Halmos G, Schally AV, Kahan Z. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix. International Journal of Oncology. 17: 367-73. PMID 10891548 DOI: 10.3892/Ijo.17.2.367 |
0.448 |
|
2000 |
Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. The Prostate. 44: 172-80. PMID 10881027 DOI: 10.1002/1097-0045(20000701)44:2<172::Aid-Pros10>3.0.Co;2-Z |
0.406 |
|
2000 |
Kahán Z, Varga JL, Schally AV, Rékási Z, Armatis P, Chatzistamou L, Czömpöly T, Halmos G. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Research and Treatment. 60: 71-9. PMID 10845811 DOI: 10.1023/A:1006363230990 |
0.417 |
|
2000 |
Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Research and Treatment. 59: 255-62. PMID 10832595 DOI: 10.1023/A:1006352401912 |
0.451 |
|
2000 |
Rekasi Z, Varga JL, Schally AV, Halmos G, Armatis P, Groot K, Czompoly T. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. Endocrinology. 141: 2120-8. PMID 10830299 DOI: 10.1210/Endo.141.6.7511 |
0.377 |
|
2000 |
Sun B, Schally AV, Halmos G. The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regulatory Peptides. 90: 77-84. PMID 10828496 DOI: 10.1016/S0167-0115(00)00114-2 |
0.336 |
|
2000 |
Szepeshazi K, Schally AV, Groot K, Armatis P, Halmos G, Herbert F, Szende B, Varga JL, Zarandi M. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. British Journal of Cancer. 82: 1724-31. PMID 10817510 DOI: 10.1054/Bjoc.2000.1223 |
0.346 |
|
2000 |
Arencibia JM, Schally AV. Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line. International Journal of Oncology. 16: 1009-13. PMID 10762638 DOI: 10.3892/Ijo.16.5.1009 |
0.45 |
|
2000 |
Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. European Journal of Cancer (Oxford, England : 1990). 36: 128-36. PMID 10741306 DOI: 10.1016/S0959-8049(99)00230-0 |
0.402 |
|
2000 |
Schally AV. LH-RH analogues: I. Their impact on reproductive medicine. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology. 13: 401-9. PMID 10685334 DOI: 10.3109/09513599909167587 |
0.353 |
|
2000 |
Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. The Prostate. 42: 295-303. PMID 10679759 DOI: 10.1002/(Sici)1097-0045(20000301)42:4<295::Aid-Pros7>3.0.Co;2-B |
0.357 |
|
2000 |
Rekasi Z, Varga JL, Schally AV, Halmos G, Groot K, Czompoly T. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro. Proceedings of the National Academy of Sciences of the United States of America. 97: 1218-23. PMID 10655511 DOI: 10.1073/Pnas.97.3.1218 |
0.453 |
|
2000 |
Nagy A, Plonowski A, Schally AV. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. Proceedings of the National Academy of Sciences of the United States of America. 97: 829-34. PMID 10639165 DOI: 10.1073/Pnas.97.2.829 |
0.43 |
|
2000 |
Kiaris H, Schally AV, Varga JL, Groot K, Armatis P. Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 96: 14894-8. PMID 10611309 DOI: 10.1073/PNAS.96.26.14894 |
0.301 |
|
2000 |
Kiaris H, Schally AV, Sun B, Armatis P, Groot K. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide. Oncogene. 18: 7168-73. PMID 10597318 DOI: 10.1038/Sj.Onc.1203213 |
0.336 |
|
1999 |
Kiaris H, Schally AV, Nagy A, Sun B, Armatis P, Szepeshazi K. Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice. British Journal of Cancer. 81: 966-71. PMID 10576652 DOI: 10.1038/Sj.Bjc.6690794 |
0.345 |
|
1999 |
Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides. 20: 1247-62. PMID 10573298 DOI: 10.1016/S0196-9781(99)00130-8 |
0.461 |
|
1999 |
Csernus V, Schally AV, Groot K. Effect of GHRH and peptides from the vasoactive intestinal peptide family on cAMP production of human cancer cell lines in vitro. The Journal of Endocrinology. 163: 269-80. PMID 10556777 DOI: 10.1677/Joe.0.1630269 |
0.416 |
|
1999 |
Schally AV, Varga JL. Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents. Trends in Endocrinology and Metabolism. 10: 383-391. PMID 10542394 DOI: 10.1016/S1043-2760(99)00209-X |
0.379 |
|
1999 |
Alvaro-Alonso I, Muñoz-Acedo G, Rodríguez-Martín E, Schally AV, Arilla E. Bombesin induces a reduction of somatostatin inhibition of adenylyl cyclase activity, Gi function, and somatostatin receptors in rat exocrine pancreas. Peptides. 20: 723-30. PMID 10477127 DOI: 10.1016/S0196-9781(99)00054-6 |
0.41 |
|
1999 |
Csernus V, Schally AV, Groot K. Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro. Peptides. 20: 843-50. PMID 10477085 DOI: 10.1016/S0196-9781(99)00071-6 |
0.412 |
|
1999 |
Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. European Journal of Endocrinology. 141: 1-14. PMID 10407215 DOI: 10.1530/Eje.0.1410001 |
0.36 |
|
1999 |
Kahán Z, Nagy A, Schally AV, Hebert F, Sun B, Groot K, Halmos G. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. International Journal of Cancer. 82: 592-8. PMID 10404076 DOI: 10.1002/(Sici)1097-0215(19990812)82:4<592::Aid-Ijc20>3.0.Co;2-0 |
0.33 |
|
1999 |
Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Cancer. 85: 2608-15. PMID 10375109 DOI: 10.1002/(SICI)1097-0142(19990615)85:12<2608::AID-CNCR17>3.0.CO;2-H |
0.321 |
|
1999 |
Halmos G, Nagy A, Lamharzi N, Schally AV. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Letters. 136: 129-36. PMID 10355741 DOI: 10.1016/S0304-3835(98)00316-4 |
0.375 |
|
1999 |
Miyazaki M, Schally AV, Nagy A, Lamharzi N, Halmos G, Szepeshazi K, Armatis P. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. American Journal of Obstetrics and Gynecology. 180: 1095-103. PMID 10329861 DOI: 10.1016/S0002-9378(99)70600-9 |
0.513 |
|
1999 |
Csernus VJ, Schally AV, Kiaris H, Armatis P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proceedings of the National Academy of Sciences of the United States of America. 96: 3098-103. PMID 10077643 DOI: 10.1073/Pnas.96.6.3098 |
0.361 |
|
1999 |
Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. The Prostate. 38: 151-8. PMID 9973101 DOI: 10.1002/(SICI)1097-0045(19990201)38:2<151::AID-PROS9>3.0.CO;2 |
0.349 |
|
1999 |
Varga JL, Schally AV, Csernus VJ, Zarándi M, Halmos G, Groot K, Rékási Z. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proceedings of the National Academy of Sciences of the United States of America. 96: 692-7. PMID 9892695 DOI: 10.1073/PNAS.96.2.692 |
0.37 |
|
1999 |
Danila DC, Schally AV, Nagy A, Alexander JM. Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 96: 669-73. PMID 9892691 DOI: 10.1073/Pnas.96.2.669 |
0.41 |
|
1999 |
Lamharzi N, Schally AV, Koppán M. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regulatory Peptides. 77: 185-92. PMID 9809814 DOI: 10.1016/S0167-0115(98)00119-0 |
0.368 |
|
1998 |
PORATH J, SCHALLY AV. Gel filtration of posterior pituitary hormones. Endocrinology. 70: 738-42. PMID 14488014 DOI: 10.1210/ENDO-70-5-738 |
0.346 |
|
1998 |
Miyazaki M, Lamharzi N, Schally AV, Halmos G, Szepeshazi K, Groot K, Cai RZ. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095. European Journal of Cancer (Oxford, England : 1990). 34: 710-7. PMID 9713279 DOI: 10.1016/S0959-8049(97)10123-X |
0.354 |
|
1998 |
Lamharzi N, Halmos G, Jungwirth A, Schally AV. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice. International Journal of Oncology. 13: 429-35. PMID 9683774 DOI: 10.3892/Ijo.13.3.429 |
0.388 |
|
1998 |
Toth K, Kovacs M, Zarandi M, Halmos G, Groot K, Nagy A, Kele Z, Schally AV. New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity. The Journal of Peptide Research : Official Journal of the American Peptide Society. 51: 134-41. PMID 9516049 DOI: 10.1111/J.1399-3011.1998.Tb00631.X |
0.406 |
|
1998 |
Srkalovic G, Schally AV, Wittliff JL, Day TG, Jenison EL. Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. International Journal of Oncology. 12: 489-98. PMID 9472084 DOI: 10.3892/IJO.12.3.489 |
0.57 |
|
1998 |
Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csernus V, Kovács M, Koppán M, Szepesházi K, Kahán Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proceedings of the National Academy of Sciences of the United States of America. 95: 1794-9. PMID 9465096 DOI: 10.1073/Pnas.95.4.1794 |
0.387 |
|
1998 |
Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 217: 143-52. PMID 9452137 DOI: 10.3181/00379727-217-44216 |
0.336 |
|
1998 |
Szepeshazi K, Schally AV, Nagy A, Halmos G, Groot K. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. Anti-Cancer Drugs. 8: 974-87. PMID 9436641 DOI: 10.1097/00001813-199711000-00009 |
0.466 |
|
1997 |
Jungwirth A, Schally A, Nagy A, Pinski J, Groot K, Galvan G, Szepeshazi K, Halmos G. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. International Journal of Oncology. 10: 877-84. PMID 21533457 DOI: 10.3892/Ijo.10.5.877 |
0.368 |
|
1997 |
Emons G, Ortmann O, Schulz KD, Schally AV. Growth-inhibitory actions of analogues of Luteinizing Hormone Releasing Hormone on tumor cells. Trends in Endocrinology and Metabolism: Tem. 8: 355-62. PMID 18406825 DOI: 10.1016/S1043-2760(97)00155-0 |
0.402 |
|
1997 |
Maria Comaru-Schally A, Schally AV. Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions. Advanced Drug Delivery Reviews. 28: 157-169. PMID 10837570 DOI: 10.1016/S0169-409X(97)00056-2 |
0.445 |
|
1997 |
Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K, Armatis P. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. Journal of the National Cancer Institute. 89: 1803-9. PMID 9392622 DOI: 10.1093/Jnci/89.23.1803 |
0.484 |
|
1997 |
Szepeshazi K, Schally AV, Halmos G, Lamharzi N, Groot K, Horvath JE. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers. Proceedings of the National Academy of Sciences of the United States of America. 94: 10913-8. PMID 9380734 DOI: 10.1073/Pnas.94.20.10913 |
0.38 |
|
1997 |
Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M, Schally AV. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II European Journal of Cancer Part A. 33: 1141-1148. PMID 9376196 DOI: 10.1016/S0959-8049(97)00072-5 |
0.388 |
|
1997 |
Kovacs M, Kineman RD, Schally AV, Zarandi M, Groot K, Frohman LA. Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly. Endocrinology. 138: 4536-42. PMID 9348175 DOI: 10.1210/ENDO.138.11.5498 |
0.349 |
|
1997 |
Yano T, Yano N, Matsumi H, Morita Y, Tsutsumi O, Schally AV, Taketani Y. Effect of luteinizing hormone-releasing hormone analogs on the rat ovarian follicle development. Hormone Research. 35-41. PMID 9267814 DOI: 10.1159/000191298 |
0.455 |
|
1997 |
Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV. Luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75) and bombesin antagonist RC-3940-11 inhibit the growth of androgen-independent PC- 3 prostate cancer in nude mice Prostate. 32: 164-172. PMID 9254895 DOI: 10.1002/(Sici)1097-0045(19970801)32:3<164::Aid-Pros2>3.0.Co;2-L |
0.431 |
|
1997 |
Jungwirth A, Schally AV, Pinski J, Halmos G, Groot K, Armatis P, Vadillo-Buenfil M. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. British Journal of Cancer. 75: 1585-92. PMID 9184172 DOI: 10.1038/Bjc.1997.271 |
0.406 |
|
1997 |
Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. 94: 5810-3. PMID 9159156 DOI: 10.1073/Pnas.94.11.5810 |
0.419 |
|
1997 |
Kovács M, Schally AV, Zarándi M, Groot K. Inhibition of GH release of rats by new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides. 18: 431-8. PMID 9145432 DOI: 10.1016/S0196-9781(96)00334-8 |
0.398 |
|
1997 |
Zarandi M, Kovacs M, Horvath JE, Toth K, Halmos G, Groot K, Nagy A, Kele Z, Schally AV. Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides. 18: 423-30. PMID 9145431 DOI: 10.1016/S0196-9781(96)00344-0 |
0.46 |
|
1997 |
Kovacs M, Schally AV, Nagy A, Koppan M, Groot K. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 94: 1420-5. PMID 9037068 DOI: 10.1073/Pnas.94.4.1420 |
0.541 |
|
1997 |
Nagy A, Armatis P, Cai RZ, Szepeshazi K, Halmos G, Schally AV. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proceedings of the National Academy of Sciences of the United States of America. 94: 652-6. PMID 9012839 DOI: 10.1073/Pnas.94.2.652 |
0.341 |
|
1997 |
Kovacs M, Zarándi M, Halmos G, Groot K, Schally AV. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action. Endocrinology. 137: 5364-9. PMID 8940358 DOI: 10.1210/ENDO.137.12.8940358 |
0.388 |
|
1997 |
Pinski J, Izdebski J, Jungwirth A, Groot K, Schally AV. Effect of chronic administration of a new potent agonist of GH-RH(1-29)NH2 on linear growth and GH responsiveness in rats. Regulatory Peptides. 65: 197-201. PMID 8897642 DOI: 10.1016/0167-0115(96)00099-7 |
0.447 |
|
1997 |
Kovács M, Halmos G, Groot K, Izdebski J, Schally AV. Chronic administration of a new potent agonist of growth hormone- releasing hormone induces compensatory linear growth in growth hormone-deficient rats: mechanism of action. Neuroendocrinology. 64: 169-76. PMID 8875434 DOI: 10.1159/000127115 |
0.43 |
|
1996 |
Emons G, Muller V, Ortmann O, Grossmann G, Trautner U, Stuckrad B, Schulz K, Schally A. Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. International Journal of Oncology. 9: 1129-37. PMID 21541621 DOI: 10.3892/Ijo.9.6.1129 |
0.341 |
|
1996 |
Pinski J, Schally AV, Jungwirth A, Groot K, Halmos G, Armatis P, Zarándi M, Vadillo-Buenfil M. Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). International Journal of Oncology. 9: 1099-1105. PMID 21541617 DOI: 10.3892/Ijo.9.6.1099 |
0.327 |
|
1996 |
BOWERS CY, SCHALLY AV. EFFECTS OF AGE, SEX, CASTRATION AND THE ADMINISTRATION OF TESTOSTERONE AND ESTRADIOL ON LEVELS OF SERUM CHOLESTERYL ESTER FATTY ACIDS IN RATS. Endocrinology. 76: 1047-54. PMID 14301509 DOI: 10.1210/Endo-76-6-1047 |
0.313 |
|
1996 |
SCHALLY AV, STEELMAN SL, BOWERS CY. EFFECT OF HYPOTHALAMIC EXTRACTS ON RELEASE OF GROWTH HORMONE IN VITRO. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 119: 208-12. PMID 14297848 DOI: 10.3181/00379727-119-30138 |
0.475 |
|
1996 |
KUROSHIMA A, ISHIDA Y, BOWERS CY, SCHALLY AV. STIMULATION OF RELEASE OF FOLLICLE-STIMULATING HORMONE BY HYPOTHALAMIC EXTRACTS IN VITRO AND IN VIVO. Endocrinology. 76: 614-9. PMID 14289181 DOI: 10.1210/Endo-76-4-614 |
0.454 |
|
1996 |
SCHALLY AV, KUROSHIMA A, ISHIDA Y, REDDING TW, BOWERS CY. THE PRESENCE OF PROLACTIN INHIBITING FACTOR (PIF) IN EXTRACTS OF BEEF, SHEEP AND PIG HYPOTHALAMI. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 118: 350-2. PMID 14268618 DOI: 10.3181/00379727-118-29839 |
0.439 |
|
1996 |
SCHALLY AV, BOWERS CY. IN VITRO AND IN VIVO STIMULATION OF THE RELEASE OF LUTEINIZING HORMONE. Endocrinology. 75: 312-20. PMID 14235397 DOI: 10.1210/Endo-75-3-312 |
0.524 |
|
1996 |
SCHALLY AV, BOWERS CY. PURIFICATION OF LUTEINIZING HORMONE-RELEASING FACTOR FROM BOVINE HYPOTHALAMUS. Endocrinology. 75: 608-14. PMID 14211906 DOI: 10.1210/Endo-75-4-608 |
0.451 |
|
1996 |
BOWERS CY, REDDING TW, SCHALLY AV. EFFECTS OF ALPHA-AND BETA-MELANOCYTE STIMULATING HORMONES AND OTHER PEPTIDES ON THE THYROID IN MICE. Endocrinology. 74: 559-66. PMID 14180149 DOI: 10.1210/Endo-74-4-559 |
0.361 |
|
1996 |
Szepeshazi K, Schally AV, Halmos G, Szoke B, Groot K, Nagy A. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers : correlations between growth characteristics and EGF receptor content of tumors Breast Cancer Research and Treatment. 40: 129-139. PMID 8879679 DOI: 10.1007/Bf01806208 |
0.375 |
|
1996 |
Emons G, Ortmann O, Teichert HM, Fassl H, Löhrs U, Kullander S, Kauppila A, Ayalon D, Schally A, Oberheuser F. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer. 78: 1452-60. PMID 8839551 DOI: 10.1002/(Sici)1097-0142(19961001)78:7<1452::Aid-Cncr12>3.0.Co;2-Z |
0.426 |
|
1996 |
Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, Kakar SS, Schally AV. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology. 137: 3430-6. PMID 8754771 DOI: 10.1210/ENDO.137.8.8754771 |
0.351 |
|
1996 |
Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, Zarandi M, Groot K, Miyazaki M, Jungwirth A, Horvath J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proceedings of the National Academy of Sciences of the United States of America. 93: 7269-73. PMID 8692981 DOI: 10.1073/Pnas.93.14.7269 |
0.468 |
|
1996 |
Casanueva FF, Perez FR, Casabiell X, Camiña JP, Cai RZ, Schally AV. Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines. Proceedings of the National Academy of Sciences of the United States of America. 93: 1406-11. PMID 8643644 DOI: 10.1073/Pnas.93.4.1406 |
0.303 |
|
1996 |
Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M, Groot K. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proceedings of the National Academy of Sciences of the United States of America. 93: 2398-402. PMID 8637885 DOI: 10.1073/PNAS.93.6.2398 |
0.373 |
|
1996 |
Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. International Journal of Cancer. 65: 870-4. PMID 8631606 DOI: 10.1002/(Sici)1097-0215(19960315)65:6<870::Aid-Ijc27>3.0.Co;2-6 |
0.33 |
|
1996 |
Kozacko MF, Mang TS, Schally AV, Priore RL, Liebow C. Bombesin antagonist prevents CO2 laser-induced promotion of oral cancer Proceedings of the National Academy of Sciences of the United States of America. 93: 2953-2957. PMID 8610149 DOI: 10.1073/Pnas.93.7.2953 |
0.308 |
|
1996 |
Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Human Reproduction (Oxford, England). 10: 1974-81. PMID 8567825 DOI: 10.1093/Oxfordjournals.Humrep.A136219 |
0.492 |
|
1995 |
Horváth JE, Groot K, Schally AV. Growth hormone-releasing hormone stimulates cAMP release in superfused rat pituitary cells. Proceedings of the National Academy of Sciences of the United States of America. 92: 1856-60. PMID 7892191 DOI: 10.1073/PNAS.92.6.1856 |
0.381 |
|
1995 |
Szepshazi K, Halmos G, Groot K, Schally AV. Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist. International Journal of Pancreatology : Official Journal of the International Association of Pancreatology. 16: 141-9. PMID 7868940 DOI: 10.1007/Bf02944324 |
0.448 |
|
1995 |
Shirahige Y, Cai RZ, Szepeshazi K, Halmos G, Pinski J, Groot K, Schally AV. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 48: 465-72. PMID 7858155 DOI: 10.1016/0753-3322(94)90007-8 |
0.357 |
|
1995 |
Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K, Schally AV. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 92: 4872-6. PMID 7761415 DOI: 10.1073/Pnas.92.11.4872 |
0.478 |
|
1995 |
Crean DH, Liebow C, Lee MT, Kamer AR, Schally AV, Mang TS. Alterations in receptor-mediated kinases and phosphatases during carcinogenesis Journal of Cancer Research and Clinical Oncology. 121: 141-149. PMID 7713985 DOI: 10.1007/Bf01198095 |
0.375 |
|
1995 |
Horváth JE, Zarándi M, Groot K, Schally AV. Effect of long-acting antagonists of growth hormone (GH)-releasing hormone on GH and cyclic adenosine 3',5'-monophosphate release in superfused rat pituitary cells. Endocrinology. 136: 3849-55. PMID 7649091 DOI: 10.1210/Endo.136.9.7649091 |
0.487 |
|
1995 |
Pinski J, Schally AV, Yano T, Groot K, Srkalovic G, Serfozo P, Reissmann T, Bernd M, Deger W, Kutscher B. Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75). International Journal of Peptide and Protein Research. 45: 410-7. PMID 7591480 DOI: 10.1111/J.1399-3011.1995.Tb01056.X |
0.379 |
|
1995 |
Qin Y, Ertl T, Cai RZ, Horvàth JE, Groot K, Schally AV. Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. International Journal of Cancer. Journal International Du Cancer. 63: 257-62. PMID 7591214 DOI: 10.1002/Ijc.2910630219 |
0.32 |
|
1995 |
Konturek SJ, Brzozowski T, Bielanski W, Schally AV. Role of endogenous gastrin in gastroprotection. European Journal of Pharmacology. 278: 203-12. PMID 7589156 DOI: 10.1016/0014-2999(95)00120-A |
0.316 |
|
1995 |
Groot K, Horvàth JE, Cai RZ, Schally AV. Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity. International Journal of Peptide and Protein Research. 45: 561-6. PMID 7558587 DOI: 10.1111/J.1399-3011.1995.Tb01320.X |
0.321 |
|
1995 |
Gonzalez-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, Fuentes-Garcia M, Cardenas-Cornejo I, Comaru-Schally AM, Schally AV. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology. 45: 275-81. PMID 7531902 DOI: 10.1016/0090-4295(95)80018-2 |
0.371 |
|
1995 |
Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M, Armatis P. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. Journal of the National Cancer Institute. 87: 1787-94. PMID 7473836 DOI: 10.1093/Jnci/87.23.1787 |
0.443 |
|
1995 |
Pinski J, Yano T, Schally AV. Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats. Neuroendocrinology. 56: 831-7. PMID 1369591 DOI: 10.1159/000126313 |
0.457 |
|
1995 |
McDonough PG, Schally AV, Halmos G, Pinski J. Terminology for Luteinizing Hormone-Releasing Hormone Antagonists Fertility and Sterility. 64: 226. DOI: 10.1016/S0015-0282(16)57696-1 |
0.499 |
|
1994 |
Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer. 73: 1229-38. PMID 8313327 DOI: 10.1002/1097-0142(19940215)73:4<1229::Aid-Cncr2820730417>3.0.Co;2-1 |
0.407 |
|
1994 |
Kleinman D, Douvdevani A, Schally AV, Levy J, Sharoni Y. Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis. American Journal of Obstetrics and Gynecology. 170: 96-102. PMID 8296852 DOI: 10.1016/S0002-9378(94)70391-4 |
0.426 |
|
1994 |
Kleinman D, Roberts CT, LeRoith D, Schally AV, Levy J, Sharoni Y. Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75. Regulatory Peptides. 48: 91-8. PMID 8265821 DOI: 10.1016/0167-0115(93)90338-9 |
0.375 |
|
1994 |
Ayalon D, Farhi Y, Comaru-Schally AM, Schally AV, Eckstein N, Vagman I, Limor R. Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat. Neuroendocrinology. 58: 153-9. PMID 8264861 DOI: 10.1159/000126527 |
0.406 |
|
1994 |
Liebow C, Crean DH, Lee MT, Kamer AR, Mang TS, Schally AV. Synergistic effects of bombesin and epidermal growth factor on cancers Proceedings of the National Academy of Sciences of the United States of America. 91: 3804-3808. PMID 8170991 DOI: 10.1073/Pnas.91.9.3804 |
0.34 |
|
1994 |
Yano T, Pinski J, Radulovic S, Schally AV. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 91: 1701-5. PMID 8127868 DOI: 10.1073/PNAS.91.5.1701 |
0.305 |
|
1994 |
Pinski J, Halmos G, Shirahige Y, Wittliff JL, Schally AV. Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486. The Journal of Clinical Endocrinology and Metabolism. 77: 1388-92. PMID 8077338 DOI: 10.1210/JCEM.77.5.8077338 |
0.562 |
|
1994 |
Qin Y, Halmos G, Cai RZ, Szoke B, Ertl T, Schally AV. Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. Journal of Cancer Research and Clinical Oncology. 120: 519-28. PMID 8045917 DOI: 10.1007/Bf01221028 |
0.354 |
|
1994 |
Reile H, Armatis PE, Schally AV. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. The Prostate. 25: 29-38. PMID 8022709 DOI: 10.1002/Pros.2990250105 |
0.315 |
|
1994 |
Szöke B, Horváth J, Halmos G, Rékási Z, Groot K, Nagy A, Schally AV. LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro. Peptides. 15: 359-66. PMID 8008640 DOI: 10.1016/0196-9781(94)90024-8 |
0.459 |
|
1994 |
Müller A, Busker E, Engel J, Kutscher B, Bernd M, Schally AV. Structural investigation of Cetrorelix, a new potent and long-acting LH-RH antagonist. International Journal of Peptide and Protein Research. 43: 264-70. PMID 8005749 DOI: 10.1111/J.1399-3011.1994.Tb00389.X |
0.431 |
|
1994 |
Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z, Schally AV. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 91: 12298-302. PMID 7991622 DOI: 10.1073/pnas.91.25.12298 |
0.37 |
|
1994 |
Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Human Reproduction (Oxford, England). 9: 1364-79. PMID 7962452 DOI: 10.1093/Oxfordjournals.Humrep.A138714 |
0.413 |
|
1994 |
Banks WA, Kastin AJ, Sam HM, Cao VT, King B, Maness LM, Schally AV. Saturable efflux of the peptides RC-160 and Tyr-MIF-1 by different parts of the blood-brain barrier. Brain Research Bulletin. 35: 179-82. PMID 7953775 DOI: 10.1016/0361-9230(94)90100-7 |
0.421 |
|
1994 |
Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai RZ. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice British Journal of Cancer. 70: 886-892. PMID 7947094 DOI: 10.1038/Bjc.1994.415 |
0.359 |
|
1994 |
Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yano T. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. Acta Oncologica (Stockholm, Sweden). 33: 693-701. PMID 7946450 DOI: 10.3109/02841869409121784 |
0.387 |
|
1994 |
Pinski J, Reile H, Halmos G, Groot K, Schally AV. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. International Journal of Cancer. 59: 51-5. PMID 7927904 DOI: 10.1002/Ijc.2910590112 |
0.474 |
|
1994 |
Halmos G, Pinski J, Szoke B, Schally AV. Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. Cancer Letters. 85: 111-8. PMID 7923093 DOI: 10.1016/0304-3835(94)90246-1 |
0.301 |
|
1994 |
Gonzalez-Barcena D, Vadillo Buenfil M, Garcia Procel E, Guerra-Arguero L, Cardenas Cornejo I, Comaru-Schally AM, Schally AV. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75). European Journal of Endocrinology. 131: 286-92. PMID 7921214 DOI: 10.1530/EJE.0.1310286 |
0.358 |
|
1994 |
Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, Schally AV. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. International Journal of Cancer. 57: 574-80. PMID 7910153 DOI: 10.1002/Ijc.2910570422 |
0.405 |
|
1994 |
Buscail L, Delesque N, Estève JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV, Vaysse N, Susini C. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2 Proceedings of the National Academy of Sciences of the United States of America. 91: 2315-2319. PMID 7907795 DOI: 10.1073/Pnas.91.6.2315 |
0.32 |
|
1994 |
Pinski J, Schally AV, Halmos G, Szepeshazi K. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. International Journal of Cancer. 55: 963-7. PMID 7902829 DOI: 10.1002/Ijc.2910550615 |
0.392 |
|
1994 |
Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proceedings of the National Academy of Sciences of the United States of America. 91: 7090-4. PMID 7518926 DOI: 10.1073/Pnas.91.15.7090 |
0.436 |
|
1994 |
Schally AV. Hypothalamic hormones Anti-Cancer Drugs. 5: 115-130. DOI: 10.1097/00001813-199404000-00001 |
0.366 |
|
1994 |
Kleinman D, Douvdevani A, Schally AV, Levy J, Sharoni Y. Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis American Journal of Obstetrics and Gynecology. 170: 96-102. DOI: 10.1016/0020-7292(94)90393-X |
0.449 |
|
1994 |
Kleinman D, Douvdevani A, Schally A, Levy J, Sharoni Y. Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis International Journal of Gynecology & Obstetrics. 47: 199-199. DOI: 10.1016/0020-7292(94)90393-X |
0.322 |
|
1993 |
Rékási Z, Szöke B, Nagy A, Groot K, Rékási ES, Schally AV. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on the function of rat pituitary cells: tests in a long term superfusion system. Endocrinology. 132: 1991-2000. PMID 8477650 DOI: 10.1210/ENDO.132.5.8477650 |
0.374 |
|
1993 |
Rekasi Z, Schally AV. A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system. Proceedings of the National Academy of Sciences of the United States of America. 90: 2146-9. PMID 8460121 DOI: 10.1073/Pnas.90.6.2146 |
0.457 |
|
1993 |
Groot K, Csernus VJ, Pinski J, Zsigo J, Rekasi Z, Zarandi M, Schally AV. Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone. International Journal of Peptide and Protein Research. 41: 162-8. PMID 8458690 DOI: 10.1111/J.1399-3011.1993.Tb00127.X |
0.386 |
|
1993 |
Pinski J, Yano T, Janaky T, Nagy A, Juhasz A, Bokser L, Groot K, Schally AV. Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats. International Journal of Peptide and Protein Research. 41: 66-73. PMID 8436447 DOI: 10.1111/J.1399-3011.1993.Tb00116.X |
0.344 |
|
1993 |
Hershkovitz E, Marbach M, Bosin E, Levy J, Roberts CT, LeRoith D, Schally AV, Sharoni Y. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. The Journal of Clinical Endocrinology and Metabolism. 77: 963-8. PMID 8408472 DOI: 10.1210/jcem.77.4.8408472 |
0.302 |
|
1993 |
Pinski J, Schally AV, Yano T, Szepeshazi K, Halmos G, Groot K, Comaru-Schally AM, Radulovic S, Nagy A. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. The Prostate. 23: 165-78. PMID 8378189 DOI: 10.1002/Pros.2990230209 |
0.438 |
|
1993 |
Pinski J, Halmos G, Szepeshazi K, Schally AV. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Cancer. 72: 3263-70. PMID 8242552 DOI: 10.1002/1097-0142(19931201)72:11<3263::Aid-Cncr2820721122>3.0.Co;2-V |
0.415 |
|
1993 |
Pinski J, Halmos G, Schally AV. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Letters. 71: 189-96. PMID 8103419 DOI: 10.1016/0304-3835(93)90115-P |
0.388 |
|
1993 |
Radulovic S, Comaru-Schally AM, Milovanovic S, Schally AV. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Pancreas. 8: 88-97. PMID 8093555 DOI: 10.1097/00006676-199301000-00016 |
0.317 |
|
1993 |
Roberge S, Schramm RD, Schally AV, Reeves JJ. Reduced postpartum anestrus of suckled beef cows treated with microencapsulated luteinizing hormone-releasing hormone analog. Journal of Animal Science. 70: 3825-30. PMID 1474020 DOI: 10.2527/1992.70123825X |
0.384 |
|
1993 |
Schally AV, Comaru-Schally AM, Gonzalez-Barcena D. Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 46: 465-71. PMID 1363977 DOI: 10.1016/0753-3322(92)90004-Q |
0.343 |
|
1993 |
Pinski J, Yano T, Groot K, Milovanovic S, Schally AV. Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats. Peptides. 13: 905-11. PMID 1336188 DOI: 10.1016/0196-9781(92)90048-8 |
0.388 |
|
1993 |
Radulović S, Milovanović S, Schally A. Binding characteristics of cytotoxic analog of luteinizing-hormone releasing hormone (LH-RH) in membrane from human and MXT mammary cancer European Journal of Cancer. 29: S123. DOI: 10.1016/0959-8049(93)91294-U |
0.349 |
|
1993 |
Emons G, Schröder B, Ortmann O, Schally AV, Schulz KD. LHRH-Anologa binden mit hoher Affinität an Endometriumkarzinomzellen und hemmen ihre Proliferation Archives of Gynecology and Obstetrics. 254: 980-981. DOI: 10.1007/978-3-642-77857-5_375 |
0.434 |
|
1993 |
Pinski J, Yano T, Szepeshazi K, Groot K, Schally AV. Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75). Journal of Andrology. 14: 164-169. DOI: 10.1002/J.1939-4640.1993.Tb00373.X |
0.447 |
|
1992 |
Milovanovic SR, Radulovic S, Schally AV. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor. Breast Cancer Research and Treatment. 24: 147-158. PMID 8443402 DOI: 10.1007/Bf01961247 |
0.317 |
|
1992 |
Radulovic S, Cai RZ, Serfozo P, Groot K, Redding TW, Pinski J, Schally AV. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi. International Journal of Peptide and Protein Research. 38: 593-600. PMID 1726427 DOI: 10.1111/J.1399-3011.1991.Tb01545.X |
0.389 |
|
1992 |
Bokser L, Srkalovic G, Szepeshazi K, Schally AV. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75). Neuroendocrinology. 54: 136-45. PMID 1662786 DOI: 10.1159/000125862 |
0.45 |
|
1992 |
Csernus VJ, Schally AV. Evaluation of luteinizing hormone-releasing hormone antagonistic activity in vitro. Proceedings of the National Academy of Sciences of the United States of America. 89: 5759-63. PMID 1631057 DOI: 10.1073/Pnas.89.13.5759 |
0.51 |
|
1992 |
Kádár T, Telegdy G, Schally AV. An LH-RH antagonist inhibits the behavioral effects of the agonist D-TRP-6-LH-RH in mice. Pharmacology, Biochemistry, and Behavior. 41: 665-8. PMID 1594632 DOI: 10.1016/0091-3057(92)90209-X |
0.389 |
|
1992 |
Roberge S, Johnson HE, Zarandi M, Schally AV, Reeves JJ. Evaluation of the biological potency of new agmatine analogs of growth hormone-releasing hormone in the bovine. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 200: 109-14. PMID 1570352 DOI: 10.3181/00379727-200-43401 |
0.481 |
|
1992 |
Pinski J, Yano T, Miller G, Schally AV. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75. The Prostate. 20: 213-24. PMID 1533453 DOI: 10.1002/Pros.2990200306 |
0.485 |
|
1992 |
Reissmann T, Hilgard P, Harleman JH, Engel J, Comaru-Schally AM, Schally AV. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone. Journal of Cancer Research and Clinical Oncology. 118: 44-49. PMID 1530849 DOI: 10.1007/Bf01192310 |
0.359 |
|
1992 |
Pinski J, Yano T, Rekasi Z, Cai RZ, Radulovic S, Schally AV. High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration. Regulatory Peptides. 41: 185-93. PMID 1438988 DOI: 10.1016/0167-0115(92)90112-8 |
0.389 |
|
1992 |
Pinski J, Yano T, Groot K, Cai RZ, Radulovic S, Schally AV. Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats. The American Journal of Physiology. 263: E712-7. PMID 1415689 DOI: 10.1152/AJPENDO.1992.263.4.E712 |
0.411 |
|
1992 |
Zarandi M, Serfozo P, Zsigo J, Bokser L, Janaky T, Olsen DB, Bajusz S, Schally AV. Potent agonists of growth hormone-releasing hormone. Part I. International Journal of Peptide and Protein Research. 39: 211-7. PMID 1399259 DOI: 10.1111/J.1399-3011.1992.Tb00791.X |
0.444 |
|
1992 |
Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Research and Treatment. 21: 35-45. PMID 1391973 DOI: 10.1007/BF01811962 |
0.314 |
|
1992 |
Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo. Anti-Cancer Drugs. 3: 109-16. PMID 1388062 DOI: 10.1097/00001813-199204000-00006 |
0.475 |
|
1992 |
Jaworek J, Konturek PK, Konturek SJ, Cai RZ, Schally AV. Actions of novel bombesin receptor antagonists on pancreatic secretion in rats. European Journal of Pharmacology. 214: 239-45. PMID 1381317 DOI: 10.1016/0014-2999(92)90124-M |
0.403 |
|
1992 |
Milovanovic SR, Radulovic S, Groot K, Schally AV. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160. The Prostate. 20: 269-80. PMID 1376910 DOI: 10.1002/Pros.2990200403 |
0.438 |
|
1992 |
Szende B, Juhasz E, Lapis K, Schally AV. Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160. Urological Research. 20: 383-386. PMID 1361084 DOI: 10.1007/Bf00294492 |
0.305 |
|
1992 |
Banks WA, Kastin AJ, Radulovic S, Conley FK, Johnson DL, Schally AV. Selective uptake of the somatostatin analog RC-160 across the blood-brain tumor barrier of mice with KHT sarcomas. Anti-Cancer Drugs. 3: 519-23. PMID 1360272 DOI: 10.1097/00001813-199210000-00012 |
0.336 |
|
1992 |
Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Research and Treatment. 21: 181-192. PMID 1355375 DOI: 10.1007/Bf01975001 |
0.391 |
|
1992 |
Radulovic SS, Milovanovic SR, Cai RZ, Schally AV. The binding of bombesin and somatostatin and their analogs to human colon cancers. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 200: 394-401. PMID 1352046 DOI: 10.3181/00379727-200-43447 |
0.304 |
|
1992 |
Yano T, Pinski J, Szepeshazi K, Milovanovic SR, Groot K, Schally AV. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model. The Prostate. 20: 297-310. PMID 1351672 DOI: 10.1002/Pros.2990200405 |
0.447 |
|
1992 |
Pinski J, Milovanovic S, Yano T, Hamaoui A, Radulovic S, Cai RZ, Schally AV. Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin analogs. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 200: 49-56. PMID 1349189 DOI: 10.3181/00379727-200-43393 |
0.403 |
|
1992 |
Brower ST, Schally AV, Redding TW, Hollander VP. Differential effects of LHRH and somatostatin analogs on human breast cancer. The Journal of Surgical Research. 52: 6-14. PMID 1347798 DOI: 10.1016/0022-4804(92)90271-Z |
0.399 |
|
1992 |
Kádár T, Telegdy G, Schally AV. Behavioral effects of centrally administered LH-RH agonist in rats. Physiology & Behavior. 51: 601-5. PMID 1326115 DOI: 10.1016/0031-9384(92)90186-6 |
0.42 |
|
1992 |
Radulovic S, Nagy A, Szoke B, Schally AV. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Letters. 62: 263-71. PMID 1317746 DOI: 10.1016/0304-3835(92)90105-5 |
0.336 |
|
1992 |
Segal-Abramson T, Kitroser H, Levy J, Schally AV, Sharoni Y. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 89: 2336-9. PMID 1312718 DOI: 10.1073/Pnas.89.6.2336 |
0.444 |
|
1991 |
Zarandi M, Csernus V, Bokser L, Bajusz S, Groot K, Schally AV. Synthesis and in vitro and in vivo activity of analogs of growth hormone-releasing hormone (GH-RH) with C-terminal agmatine. International Journal of Peptide and Protein Research. 36: 499-505. PMID 2090641 DOI: 10.1111/J.1399-3011.1990.Tb00988.X |
0.436 |
|
1991 |
Szepeshazi K, Korkut E, Szende B, Lapis K, Schally AV. Histological changes in Dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75. The Prostate. 18: 255-70. PMID 2020621 DOI: 10.1002/Pros.2990180307 |
0.382 |
|
1991 |
Korkut E, Bokser L, Comaru-Schally AM, Groot K, Schally AV. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75. Proceedings of the National Academy of Sciences of the United States of America. 88: 844-8. PMID 1992476 DOI: 10.1073/Pnas.88.3.844 |
0.425 |
|
1991 |
Monsonego J, Destable MD, De Saint Florent G, Amouroux J, Kouyoundjian JC, Haour F, Breau JL, Israel L, Comaru-Schally AM, Schally AV. Fibrocystic disease of the breast in premenopausal women: histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment. American Journal of Obstetrics and Gynecology. 164: 1181-9. PMID 1852100 DOI: 10.1016/0002-9378(91)90680-P |
0.346 |
|
1991 |
Liebow C, Lee MT, Kamer AR, Schally AV. Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America. 88: 2244-8. PMID 1672452 DOI: 10.1073/Pnas.88.6.2244 |
0.316 |
|
1991 |
Qin Y, Schally AV, Willems G. Somatostatin analogue RC-160 inhibits the growth of transplanted colon cancer in rats International Journal of Cancer. 47: 765-770. PMID 1672306 DOI: 10.1002/Ijc.2910470524 |
0.317 |
|
1991 |
Lee MT, Liebow C, Kamer AR, Schally AV. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors Proceedings of the National Academy of Sciences of the United States of America. 88: 1656-1660. PMID 1672042 DOI: 10.1073/Pnas.88.5.1656 |
0.401 |
|
1990 |
Arimura A, Saito T, Schally AV. Assays for corticotropin-releasing factor (CRF) using rats treated with morphine, chlorpromazine, dexamethasone and Nembutal. Endocrinology. 81: 235-45. PMID 4951998 DOI: 10.1210/Endo-81-2-235 |
0.339 |
|
1990 |
Edwards BF, Redding TW, Schally AV. The effect of gastrointestinal hormones on the incorporation of tritiated thymidine in the pancreatic adenocarcinoma cell line (WD PaCa). International Journal of Pancreatology : Official Journal of the International Association of Pancreatology. 5: 191-201. PMID 2600453 DOI: 10.1007/Bf02924419 |
0.382 |
|
1990 |
Srkalovic G, Szende B, Redding TW, Groot K, Schally AV. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 192: 209-18. PMID 2574866 DOI: 10.3181/00379727-192-42987 |
0.383 |
|
1990 |
Szende B, Redding TW, Schally AV. Suppression of meiosis of male germ cells by an antagonist of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 87: 901-3. PMID 2405399 DOI: 10.1073/Pnas.87.3.901 |
0.459 |
|
1990 |
Bokser L, Bajusz S, Groot K, Schally AV. Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75. Proceedings of the National Academy of Sciences of the United States of America. 87: 7100-4. PMID 2205853 DOI: 10.1073/PNAS.87.18.7100 |
0.381 |
|
1990 |
Szende B, Srkalovic G, Groot K, Lapis K, Schally AV. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. Journal of the National Cancer Institute. 82: 513-7. PMID 2156080 DOI: 10.1093/Jnci/82.6.513 |
0.45 |
|
1990 |
Redding TW, Schally AV. Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists. The Journal of Endocrinology. 126: 309-15. PMID 2144873 DOI: 10.1677/Joe.0.1260309 |
0.389 |
|
1990 |
Csernus VJ, Szende B, Schally AV. Release of peptides from sustained delivery systems (microcapsules and microparticles) in vivo. A histological and immunohistochemical study. International Journal of Peptide and Protein Research. 35: 557-65. PMID 2144847 DOI: 10.1111/J.1399-3011.1990.Tb00262.X |
0.357 |
|
1990 |
Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. British Journal of Cancer. 61: 861-5. PMID 2142603 DOI: 10.1038/bjc.1990.192 |
0.353 |
|
1990 |
Zorn JR, Mathieson J, Risquez F, Comaru-Schally AM, Schally AV. Treatment of endometriosis with a delayed release preparation of the agonist D-Trp6-luteinizing hormone-releasing hormone: long-term follow-up in a series of 50 patients. Fertility and Sterility. 53: 401-6. PMID 2137792 DOI: 10.1016/S0015-0282(16)53330-5 |
0.427 |
|
1990 |
Kádár T, Telegdy G, Schally AV. Partial reversal of behavioral action of the agonist D-Trp-6-LH-RH by naloxone in mice. Life Sciences. 46: 463-70. PMID 2137549 DOI: 10.1016/0024-3205(90)90001-8 |
0.366 |
|
1990 |
Bokser L, Zarandi M, Schally AV. Evaluation of in vivo [corrected] biological activity of new agmatine analogs of growth hormone-releasing hormone (GH-RH) Life Sciences. 46: 999-1005. PMID 2109164 DOI: 10.1016/0024-3205(90)90023-K |
0.386 |
|
1990 |
Varea J, Paredes M, Garces G, Ochoa C, Avila C, Coloma MJ, Briones R, Comaru-Schally AM, Schally AV. Effect of Somatostatin on TSH levels in non-toxic sporadic goiter. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Mã©Tabolisme. 22: 627-31. PMID 1981767 DOI: 10.1055/s-2007-1004989 |
0.33 |
|
1990 |
Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, Korkut E, Cai RZ, Szepeshazi K, Radulovic S, Bokser L, Groot K, Serfozo P, Comaru-Schally AM. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies. The Journal of Steroid Biochemistry and Molecular Biology. 37: 1061-1067. PMID 1981009 DOI: 10.1016/0960-0760(90)90466-X |
0.394 |
|
1990 |
Schally AV, Colaluca J, Paulson D, Carter WH, Neitzschman HR, Lafaye H, Cai RZ. Effect of somatostatin analogs on gastric acid secretion in dogs and rats. International Journal of Peptide and Protein Research. 36: 267-74. PMID 1980670 DOI: 10.1111/J.1399-3011.1990.Tb00977.X |
0.336 |
|
1990 |
Banks WA, Schally AV, Barrera CM, Fasold MB, Durham DA, Csernus VJ, Groot K, Kastin AJ. Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Proceedings of the National Academy of Sciences of the United States of America. 87: 6762-6. PMID 1975697 DOI: 10.1073/Pnas.87.17.6762 |
0.447 |
|
1990 |
Szende B, Srkalovic G, Schally AV, Lapis K, Groot K. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression. Cancer. 65: 2279-90. PMID 1971771 DOI: 10.1002/1097-0142(19900515)65:10<2279::Aid-Cncr2820651020>3.0.Co;2-3 |
0.402 |
|
1990 |
Srkalovic G, Cai RZ, Schally AV. Evaluation of receptors for somatostatin in various tumors using different analogs. The Journal of Clinical Endocrinology and Metabolism. 70: 661-9. PMID 1968467 DOI: 10.1210/Jcem-70-3-661 |
0.311 |
|
1990 |
Schally AV, Redding TW, Arimura A, Dupont A, Linthicum GL. Isolation of gamma-amino butyric acid from pig hypothalami and demonstration of its prolactin release-inhibiting (PIF) activity in vivo and in vitro. Endocrinology. 100: 681-91. PMID 401021 DOI: 10.1210/Endo-100-3-681 |
0.384 |
|
1989 |
Bowers CY, Lee KL, Schally AV. Effect of actinomycin D on hormones that control the release of thyrotropin from the anterior pituitary glands of mice. Endocrinology. 82: 303-10. PMID 5006435 DOI: 10.1210/Endo-82-2-303 |
0.352 |
|
1989 |
Schally AV, Muller EE, Sawano S. Effect of porcine growth hormone-releasing factor on the release and synthesis of growth hormone in vitro. Endocrinology. 82: 271-6. PMID 4952724 DOI: 10.1210/Endo-82-2-271 |
0.504 |
|
1989 |
Grings EE, Scarborough R, Schally AV, Reeves JJ. Response to a growth hormone-releasing hormone analog in heifers treated with recombinant growth hormone. Domestic Animal Endocrinology. 5: 47-53. PMID 3147164 DOI: 10.1016/0739-7240(88)90025-2 |
0.333 |
|
1989 |
Roberts AJ, Chang CF, Schally AV, Reeves JJ. Luteinizing hormone concentrations in serum of postpartum beef cows injected with microencapsulated luteinizing hormone-releasing hormone analog Journal of Animal Science. 67: 2730-2734. PMID 2681111 DOI: 10.2527/Jas1989.67102730X |
0.332 |
|
1989 |
Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV. Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas. 4: 521-8. PMID 2573055 DOI: 10.1097/00006676-198910000-00001 |
0.383 |
|
1989 |
Fekete M, Wittliff JL, Schally AV. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. Journal of Clinical Laboratory Analysis. 3: 137-47. PMID 2569034 DOI: 10.1002/jcla.1860030302 |
0.554 |
|
1989 |
Szende B, Schally AV, Srkalovic G, Comaru-Schally A, Wittliff J. Adverse Effect Of Tamoxifen With Lhrh Agonist On Oestrogen-Receptor-Negative Mammary Carcinoma The Lancet. 334: 222-223. PMID 2568553 DOI: 10.1016/S0140-6736(89)90409-1 |
0.547 |
|
1989 |
Fekete M, Zalatnai A, Schally AV. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer. Cancer Letters. 45: 87-91. PMID 2567204 DOI: 10.1016/0304-3835(89)90141-9 |
0.372 |
|
1989 |
Zalatnai A, Schally AV. Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. Histological evidence of improvement. International Journal of Pancreatology : Official Journal of the International Association of Pancreatology. 4: 149-60. PMID 2566638 DOI: 10.1007/Bf02931317 |
0.457 |
|
1989 |
Szende B, Zalatnai A, Schally AV. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proceedings of the National Academy of Sciences of the United States of America. 86: 1643-7. PMID 2564204 DOI: 10.1073/PNAS.86.5.1643 |
0.316 |
|
1989 |
Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV. Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6. Proceedings of the National Academy of Sciences of the United States of America. 86: 6318-22. PMID 2548207 DOI: 10.1073/Pnas.86.16.6318 |
0.462 |
|
1989 |
Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV. Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 86: 6313-7. PMID 2548206 DOI: 10.1073/pnas.86.16.6313 |
0.345 |
|
1989 |
González-Barcena D, Ibarra-Olmos MA, García-Carrasco F, Gutiérrez-Samperio C, Comaru-Schally AM, Schally AV. Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 43: 313-7. PMID 2529000 DOI: 10.1016/0753-3322(89)90014-0 |
0.411 |
|
1989 |
Rubio MA, Cabranes JA, Schally AV, Charro AL. Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients. The Journal of Clinical Endocrinology and Metabolism. 69: 444-7. PMID 2526819 DOI: 10.1210/Jcem-69-2-444 |
0.425 |
|
1989 |
Gonzalez-Barcena D, Perez-Sanchez PL, Graef A, Gomez AM, Berea H, Comaru-Schally AM, Schally AV. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma. The Prostate. 14: 291-300. PMID 2526325 DOI: 10.1002/Pros.2990140402 |
0.459 |
|
1989 |
Bokser L, Zalatnai A, Schally AV. Inhibition of pituitary-gonadal axis in mice by long-term administration of D-Trp-6-LHRH microcapsules. Journal of Reproduction and Fertility. 85: 569-74. PMID 2522987 DOI: 10.1530/Jrf.0.0850569 |
0.358 |
|
1988 |
Scarborough R, Gulyas J, Schally AV, Reeves JJ. Analogs of growth hormone-releasing hormone induce release of growth hormone in the bovine. Journal of Animal Science. 66: 1386-92. PMID 3135287 DOI: 10.2527/Jas1988.6661386X |
0.395 |
|
1988 |
Ayalon D, Ben-David M, Wohl R, Jaffe R, Vagman I, Eckstein N, Limor R, Comaru-Schally AM, Schally AV. Induction of ovulation with d-trp6-LHRH combined with purified FSH in patients with polycystic ovarian disease Gynecological Endocrinology. 2: 319-330. PMID 2976573 DOI: 10.3109/09513598809107655 |
0.328 |
|
1988 |
Pour PM, Redding TW, Paz-Bouza JI, Schally AV. Treatment of experimental ovarian carcinoma with monthly injection of the agonist D-Trp-6-LH-RH: a preliminary report. Cancer Letters. 41: 105-10. PMID 2968836 DOI: 10.1016/0304-3835(88)90061-4 |
0.366 |
|
1988 |
Parmar H, Rustin G, Lightman SL, Phillips RH, Hanham IW, Schally AV. Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. British Medical Journal (Clinical Research Ed.). 296: 1229. PMID 2968130 DOI: 10.1136/Bmj.296.6631.1229 |
0.447 |
|
1988 |
Karashima T, Zalatnai A, Schally AV. Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats. Proceedings of the National Academy of Sciences of the United States of America. 85: 2329-33. PMID 2965391 DOI: 10.1073/PNAS.85.7.2329 |
0.325 |
|
1988 |
Bokser L, Schally AV. Delayed release formulation of the somatostatin analog RC-160 inhibits the growth hormone (GH) response to GH-releasing factor-(1-29)NH2 and decreases elevated prolactin levels in rats. Endocrinology. 123: 1735-9. PMID 2901338 DOI: 10.1210/Endo-123-4-1735 |
0.468 |
|
1988 |
Kadar T, Redding TW, Ben-David M, Schally AV. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin. Proceedings of the National Academy of Sciences of the United States of America. 85: 890-4. PMID 2893378 DOI: 10.1073/PNAS.85.3.890 |
0.365 |
|
1988 |
Pawlikowski M, Zelazowski P, Stepien H, Schally AV. Somatostatin and its analog enhance the formation of human leukocyte migration inhibiting factor: further evidence for immunomodulatory action of somatostatin. Peptides. 8: 951-2. PMID 2893363 DOI: 10.1016/0196-9781(87)90087-8 |
0.31 |
|
1988 |
Kovacs M, Gulyas J, Bajusz S, Schally AV. An evaluation of intravenous, subcutaneous, and in vitro activity of new agmatine analogs of growth hormone-releasing hormone hGH-RH (1-29)NH2. Life Sciences. 42: 27-35. PMID 2892105 DOI: 10.1016/0024-3205(88)90621-2 |
0.457 |
|
1988 |
Konturek SJ, Bilski J, Jaworek J, Tasler J, Schally AV. Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 187: 241-9. PMID 2448802 DOI: 10.3181/00379727-187-42661 |
0.411 |
|
1988 |
Paz-Bouza J, Schor N, Monje E, Redding T, Schally A. Histological Findings in the Rat Prostate Cancer Model During Treatment With a Luteinizing Hormone-Releasing Hormone Agonist and Novantrone Journal of Urology. 139: 215-215. DOI: 10.1016/S0022-5347(17)42360-3 |
0.32 |
|
1988 |
Perl V, Marquez J, Schally A. Treatment of leiomyomata uteri with D‐Trpsup 6‐luteinizing hormone‐releasing hormone International Journal of Gynecology & Obstetrics. 27: 318-318. DOI: 10.1016/0020-7292(88)90074-4 |
0.369 |
|
1987 |
Schally AV. Treatment of hormone-dependent cancer with analogues of hypothalamic hormones. Experimental and clinical studies. Annals of the New York Academy of Sciences. 496: 602-7. PMID 3474992 DOI: 10.1111/J.1749-6632.1987.Tb35820.X |
0.409 |
|
1987 |
Guoth J, Olsen DB, Kovacs M, Schally AV. Synthesis, purification and biological evaluation of porcine corticotropin-releasing factor. Life Sciences. 41: 1003-10. PMID 3039275 DOI: 10.1016/0024-3205(87)90689-8 |
0.355 |
|
1987 |
Casanueva FF, Villanueva L, Diaz Y, Devesa J, Fernandez-Cruz A, Schally AV. Atropine selectively blocks GHRH-induced GH secretion without altering LH, FSH, TSH, PRL and ACTH/cortisol secretion elicited by their specific hypothalamic releasing factors. Clinical Endocrinology. 25: 319-23. PMID 3024879 DOI: 10.1111/J.1365-2265.1986.Tb01697.X |
0.496 |
|
1987 |
Lahlou N, Roger M, Chaussain JL, Feinstein MC, Sultan C, Toublanc JE, Schally AV, Scholler R. Gonadotropin and α-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty Journal of Clinical Endocrinology and Metabolism. 65: 946-953. PMID 2959680 DOI: 10.1210/JCEM-65-5-946 |
0.331 |
|
1987 |
Perl V, Marquez J, Schally AV, Comaru-Schally AM, Leal G, Zacharias S, Gomez-Lira C. Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone. Fertility and Sterility. 48: 383-9. PMID 2957235 DOI: 10.1016/S0015-0282(16)59403-5 |
0.459 |
|
1987 |
Paz-Bouza JI, Schor NA, Monje E, Redding TW, Schally AV. Histological findings in the rat prostate cancer model during treatment with a luteinizing hormone-releasing hormone agonist and novantrone. The Prostate. 10: 291-302. PMID 2955293 DOI: 10.1002/PROS.2990100403 |
0.309 |
|
1987 |
Rubio MA, Torres-Aleman I, Calle JR, Cabranes JA, Schally AV, Charro AL. D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men. The Journal of Clinical Endocrinology and Metabolism. 65: 368-9. PMID 2954994 DOI: 10.1210/Jcem-65-2-368 |
0.653 |
|
1987 |
Schally AV, Paz-Bouza JI, Schlosser JV, Karashima T, Debeljuk L, Gandle B, Sampson M. Protective effects of analogs of luteinizing hormone-releasing hormone against x-radiation-induced testicular damage in rats. Proceedings of the National Academy of Sciences of the United States of America. 84: 851-5. PMID 2949328 DOI: 10.1073/Pnas.84.3.851 |
0.44 |
|
1987 |
Sellers KJ, Smith MS, Rojas FJ, Asch RH, Schally AV, Bartke A. Effects of a long-acting LHRH agonist preparation on plasma gonadotropin and prolactin levels in castrated male rats and on the release of prolactin from ectopic pituitaries. Regulatory Peptides. 15: 219-28. PMID 2947272 DOI: 10.1016/0167-0115(86)90063-7 |
0.45 |
|
1987 |
Schally AV, Redding TW. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 84: 7275-9. PMID 2890164 DOI: 10.1073/PNAS.84.20.7275 |
0.312 |
|
1987 |
Casanueva FF, Villanueva L, Dieguez C, Diaz Y, Cabranes JA, Szoke B, Scanlon MF, Schally AV, Fernandez-Cruz A. Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary. The Journal of Clinical Endocrinology and Metabolism. 65: 634-42. PMID 2888782 DOI: 10.1210/JCEM-65-4-634 |
0.343 |
|
1987 |
Karashima T, Cai RZ, Schally AV. Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release. Life Sciences. 41: 1011-9. PMID 2886886 DOI: 10.1016/0024-3205(87)90690-4 |
0.339 |
|
1987 |
Karashima T, Olsen D, Schally AV. Effect of long-term administration of an analog of growth hormone-releasing factor on the GH response in rats. Life Sciences. 40: 2437-44. PMID 2884550 DOI: 10.1016/0024-3205(87)90759-4 |
0.378 |
|
1987 |
Karashima T, Schally AV. Inhibitory effects of somatostatin analogs on prolactin secretion in rats pretreated with estrogen or haloperidol. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 185: 69-75. PMID 2883661 DOI: 10.3181/00379727-185-42518 |
0.335 |
|
1987 |
Paz-Bouza JI, Redding TW, Schally AV. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 84: 1112-6. PMID 2881296 DOI: 10.1073/PNAS.84.4.1112 |
0.308 |
|
1987 |
Schally A, Comaru-Schally A. Use of Luteinizing Hormone - Releasing Hormone Analogs in the Treatment of Hormone-Dependent Tumors Seminars in Reproductive Medicine. 5: 389-398. DOI: 10.1055/S-2007-1021885 |
0.363 |
|
1986 |
Schally AV, Redding TW, Comaru-Schally AM. Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH. Medical Oncology and Tumor Pharmacotherapy. 1: 109-18. PMID 6242477 DOI: 10.1007/BF02934982 |
0.32 |
|
1986 |
Debeljuk L, Torres-Aleman I, Schally AV. Effect of an antagonistic analog of LH-RH on haloperidol-induced hyperprolactinemia in female rats. Peptides. 6: 463-5. PMID 3906589 DOI: 10.1016/0196-9781(85)90111-1 |
0.658 |
|
1986 |
Ben-David M, Kadar T, Schally AV. Micromethod for the determination of free and total prolactin receptors: measurement of receptor levels in normal and malignant mammary and prostate tissues. Proceedings of the National Academy of Sciences of the United States of America. 83: 8375-9. PMID 3534889 DOI: 10.1073/Pnas.83.21.8375 |
0.365 |
|
1986 |
Józsa R, Vigh S, Mess B, Schally AV. Ontogenetic development of corticotropin-releasing factor (CRF)-containing neural elements in the brain of the chicken during incubation and after hatching. Cell and Tissue Research. 244: 681-5. PMID 3487385 DOI: 10.1007/Bf00212549 |
0.331 |
|
1986 |
Casanueva FF, Villanueva L, Dieguez C, Cabranes JA, Diaz Y, Szoke B, Scanlon MF, Schally AV, Fernandez-Cruz A. Atropine blockade of growth hormone (GH)-releasing hormone-induced GH secretion in man is not exerted at pituitary level. The Journal of Clinical Endocrinology and Metabolism. 62: 186-91. PMID 3079600 DOI: 10.1210/JCEM-62-1-186 |
0.335 |
|
1986 |
Horvath J, Ertl T, Schally AV. Effect of atrial natriuretic peptide on gonadotropin release in superfused rat pituitary cells. Proceedings of the National Academy of Sciences of the United States of America. 83: 3444-6. PMID 3010298 DOI: 10.1073/Pnas.83.10.3444 |
0.523 |
|
1986 |
Mathé G, Schally AV, Comaru-Schally AM, Mauvernay RY, Vovan ML, Machover D, Misset JL, Court B, Bouchard P, Duchier J. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents. The Prostate. 9: 327-42. PMID 2947053 DOI: 10.1002/Pros.2990090404 |
0.358 |
|
1986 |
Schally AV, Kook AI, Monje E, Redding TW, Paz-Bouza JI. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model. Proceedings of the National Academy of Sciences of the United States of America. 83: 8764-8. PMID 2946045 DOI: 10.1073/PNAS.83.22.8764 |
0.345 |
|
1986 |
Zárate A, Fonseca ME, Mason M, Tapia R, Miranda R, Kovacs K, Schally AV. Gonadotropin-secreting pituitary adenoma with concomitant hypersecretion of testosterone and elevated sperm count. Treatment with LRH agonist. Acta Endocrinologica. 113: 29-34. PMID 2945349 DOI: 10.1530/Acta.0.1130029 |
0.31 |
|
1986 |
Gonzalez-Barcena D, Perez-Sanchez P, Berea-Dominguez H, Graef-Sanchez A, Becerril-Morales M, Comaru-Schally AM, Schally AV. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH. The Prostate. 9: 207-15. PMID 2944084 DOI: 10.1002/Pros.2990090211 |
0.418 |
|
1986 |
Torres-Alemán I, Debeljuk L, Schally AV. Effects of in vivo pretreatment with D-Trp-6-LH-RH on prolactin and LH secretion by pituitary glands in vitro. Peptides. 6: 993-5. PMID 2934690 DOI: 10.1016/0196-9781(85)90333-X |
0.658 |
|
1986 |
Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proceedings of the National Academy of Sciences of the United States of America. 83: 1896-900. PMID 2869490 DOI: 10.1073/PNAS.83.6.1896 |
0.312 |
|
1986 |
Kinarti H, Keret R, Josefsberg Z, Szoke B, Schally AV, Laron Z. hGH RESPONSE TO REPEATED GH-RH 1-44 ADMINISTRATION IN HYPOPITUITARY CHILDREN Pediatric Research. 20: 1188-1188. DOI: 10.1203/00006450-198611000-00090 |
0.322 |
|
1986 |
Ertl T, Horváth J, Schally AV. 45 EFFECT OF ATRIAL NATRIURETIC PEPTIDE ON THE HORMONE RELEASE IN SUPERFUSED RAT PITUITARY CELLS Pediatric Research. 20: 1041-1041. DOI: 10.1203/00006450-198610000-00099 |
0.468 |
|
1986 |
Roger M, Duchier J, Lahlou N, Nahoul K, Schally A. Treatment of Prostatic Carcinoma with D-Trp-6-LH-RH: Plasma Hormone Levels After Daily Subcutaneous Injections and Periodic Administration of Delayed-Release Preparations Journal of Urology. 135: 657-657. DOI: 10.1016/S0022-5347(17)45783-1 |
0.314 |
|
1985 |
Merchenthaler I, Vigh S, Schally AV, Stumpf WE, Arimura A. Immunocytochemical localization of corticotropin releasing factor (CRF)-like immunoreactivity in the thalamus of the rat. Brain Research. 323: 119-22. PMID 6151862 DOI: 10.1016/0006-8993(84)90272-5 |
0.419 |
|
1985 |
Asch RH, Balmaceda JP, Castro MND, Schally AV. Comparison of the subcutaneous and intranasal administration of an LH-RH antagonist ([N-Ac-d-p-Cl-Phe1,2, d-Trp3, d-Arg6, d-Ala10]-LH-RH) in the rhesus monkey Advances in Contraception. 1: 109-117. PMID 3939508 DOI: 10.1007/Bf01849792 |
0.404 |
|
1985 |
Pertzelan A, Keret R, Bauman B, Ben-Zeev Z, Olsen DB, Szoke B, Comaru-Schally AM, Schally AV, Laron Z. Plasma growth hormone response to synthetic GH-RH1-44 in 52 children and adults with growth hormone deficiency of various etiologies. Hormone Research. 22: 24-31. PMID 3928474 DOI: 10.1159/000180068 |
0.375 |
|
1985 |
Debeljuk L, Torres-Aleman I, Schally AV. Antiserum to LH-RH blocks haloperidol-induced hyperprolactinemia in female rats. Neuroendocrinology. 40: 185-7. PMID 3883215 DOI: 10.1159/000124071 |
0.651 |
|
1985 |
Fekete M, Balázs M, Telegdy G, Schally AV. Effects of intracerebroventricular administration of ovine corticotropin-releasing factor (CRF 1-41) on passive avoidance behaviour: lack of influence on monoamine contents of limbic brain areas. Neuropeptides. 6: 283-292. PMID 3876519 DOI: 10.1016/0143-4179(85)90001-0 |
0.41 |
|
1985 |
Konturek SJ, Bilski J, Pawlik W, Thor P, Czarnobilski K, Szoke B, Schally AV. Gastrointestinal secretory, motor and circulatory effects of corticotropin releasing factor (CRF). Life Sciences. 37: 1231-40. PMID 3876499 DOI: 10.1016/0024-3205(85)90135-3 |
0.382 |
|
1985 |
Debeljuk L, Torres-Alemán I, Schally AV. D-Trp-6-luteinizing hormone-releasing hormone inhibits hyperprolactinemia in female rats. Endocrinology. 116: 2227-31. PMID 3158510 DOI: 10.1210/Endo-116-6-2227 |
0.681 |
|
1985 |
Lewis RW, Dowling KJ, Schally AV. D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons. Proceedings of the National Academy of Sciences of the United States of America. 82: 2975-9. PMID 3157995 DOI: 10.1073/Pnas.82.9.2975 |
0.412 |
|
1985 |
Schally AV, Redding TW. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model. Proceedings of the National Academy of Sciences of the United States of America. 82: 2498-502. PMID 3157990 DOI: 10.1073/PNAS.82.8.2498 |
0.328 |
|
1985 |
Redding TW, Schally AV. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model. The Prostate. 6: 219-32. PMID 3157927 DOI: 10.1016/S0022-5347(17)47333-2 |
0.438 |
|
1985 |
Asch RH, Rojas FJ, Bartke A, Schally AV, Tice TR, Klemcke HG, Siler-Khodr TM, Bray RE, Hogan MP. Prolonged suppression of plasma LH levels in male rats after a single injection of an LH-RH agonist in poly(DL-lactide-co-glycolide) microcapsules. Journal of Andrology. 6: 83-8. PMID 3157667 DOI: 10.1002/J.1939-4640.1985.Tb00821.X |
0.465 |
|
1985 |
Hierowski MT, Schally AV. An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH. Hormone Research. 21: 124-35. PMID 3156799 DOI: 10.1159/000180036 |
0.338 |
|
1985 |
Mason-Garcia M, Vigh S, Comaru-Schally AM, Redding TW, Somogyvari-Vigh A, Horvath J, Schally AV. Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations. Proceedings of the National Academy of Sciences of the United States of America. 82: 1547-51. PMID 3156381 DOI: 10.1073/PNAS.82.5.1547 |
0.364 |
|
1985 |
Vécsei L, Telegdy G, Bollók I, Schally AV. The role of central dopaminergic systems in the behavioral effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH. Neuropeptides. 6: 183-90. PMID 2991806 DOI: 10.1016/0143-4179(85)90089-7 |
0.301 |
|
1985 |
Parmar H, Phillips RH, Lightman SL, Edwards L, Allen L, Schally AV. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet (London, England). 2: 1201-5. PMID 2866289 DOI: 10.1016/S0140-6736(85)90739-1 |
0.385 |
|
1985 |
Konturek SJ, Kwiecień N, Obtułowicz W, Bielański W, Oleksy J, Schally AV. Effects of somatostatin-14 and somatostatin-28 on plasma hormonal and gastric secretory responses to cephalic and gastrointestinal stimulation in man. Scandinavian Journal of Gastroenterology. 20: 31-8. PMID 2859650 DOI: 10.3109/00365528509089629 |
0.364 |
|
1985 |
Torres-Aleman I, Redding TW, Schally AV. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 82: 1252-6. PMID 2858096 DOI: 10.1073/Pnas.82.4.1252 |
0.635 |
|
1985 |
Kauli R, Kalter-Leibovici O, Schally AV, Comaru-Schally AM, Szoke B, Laron Z. 190 LONG TERM THERAPY OF PRECOCIOUS PUBERTY WITH THE SUPERACTIVE LH-RH ANALOGUE D-TRP-6-LH-RH Pediatric Research. 19: 635-635. DOI: 10.1203/00006450-198506000-00210 |
0.365 |
|
1985 |
Bauman B, Pertzelan A, Josefsberg Z, Kaufman H, Ben Zeev Z, Schally AV, Laron Z. 87 EFFECT OF CRF 1–41 AS COMPARED TO INSULIN HYPOGLYCEMIA (ITT) ON PLASMA CORTISOL AND ACTH IN SUBJECTS WITH INTACT OR DEFECTIVE HYPOTHALAMIC-PITUITARY FUNCTIONS Pediatric Research. 19: 618-618. DOI: 10.1203/00006450-198506000-00107 |
0.375 |
|
1985 |
Lengv�ri I, Liposits Z, Vigh S, Schally A, Flerk� B. The origin and ultrastructural characteristics of corticotropin-releasing factor (CRF)-immunoreactive nerve fibers in the posterior pituitary of the rat Cell and Tissue Research. 240. DOI: 10.1007/Bf00222361 |
0.334 |
|
1985 |
Roger M, Lahlou N, Nahoul K, Duchier J, Schally AV. Treatment of prostatic carcinoma with D‐Trp‐6‐LH‐RH: Plasma hormone levels after daily subcutaneous injections and periodic administration of delayed‐release preparations The Prostate. 7: 271-282. DOI: 10.1002/Pros.2990070304 |
0.33 |
|
1984 |
Vécsei L, Bollók I, Telegdy G, Schally AV. Comparative studies with beta-(Tyr9)melanotropin-(9-18) and amphetamine on open-field behavior and striatal dopamine uptake and release. Pharmacological Research Communications. 16: 689-97. PMID 6473485 DOI: 10.1016/S0031-6989(84)80047-8 |
0.338 |
|
1984 |
Laron Z, Keret R, Bauman B, Pertzelan A, Ben-Zeev Z, Olsen DB, Comaru-Schally AM, Schally AV. Differential diagnosis between hypothalamic and pituitary hGH deficiency with the aid of synthetic GH-RH 1-44. Clinical Endocrinology. 21: 9-12. PMID 6430606 DOI: 10.1111/J.1365-2265.1984.Tb00130.X |
0.359 |
|
1984 |
Merchenthaler I, Hynes MA, Vigh S, Schally AV, Petrusz P. Corticotropin releasing factor (CRF): Origin and course of afferent pathways to the median eminence (ME) of the rat hypothalamus Neuroendocrinology. 39: 296-306. PMID 6387524 DOI: 10.1159/000123996 |
0.36 |
|
1984 |
Burgos-Briceño LA, Schally AV, Bartke A, Asch RH. Inhibition of serum luteinizing hormone and testosterone with an inhibitory analog of luteinizing hormone-releasing hormone in adult male rhesus monkeys. The Journal of Clinical Endocrinology and Metabolism. 59: 601-7. PMID 6384248 DOI: 10.1210/jcem-59-4-601 |
0.316 |
|
1984 |
Józsa R, Vigh S, Schally AV, Mess B. Localization of corticotropin-releasing factor-containing neurons in the brain of the domestic fowl. An immunohistochemical study. Cell and Tissue Research. 236: 245-8. PMID 6370454 DOI: 10.1007/Bf00216537 |
0.33 |
|
1984 |
Cehovic G, Redding TW, Hierowski MT, Schally AV. Endogenous phosphorylation in Dunning prostate tumors of rats treated with LH-RH analogues. The Prostate. 5: 605-11. PMID 6238290 DOI: 10.1016/S0022-5347(17)49291-3 |
0.356 |
|
1984 |
Redding TW, Schally AV, Tice TR, Meyers WE. Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules. Proceedings of the National Academy of Sciences of the United States of America. 81: 5845-8. PMID 6237365 DOI: 10.1073/PNAS.81.18.5845 |
0.376 |
|
1984 |
Kauli R, Pertzelan A, Ben-Zeev Z, Lewin RP, Kaufman H, Schally AM, Schally AV, Laron Z. Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate-further experience. Clinical Endocrinology. 20: 377-87. PMID 6232020 DOI: 10.1111/J.1365-2265.1984.Tb03433.X |
0.379 |
|
1984 |
Vigh S, Schally AV. Interaction between hypothalamic peptides in a superfused pituitary cell system. Peptides. 241-7. PMID 6207510 DOI: 10.1016/0196-9781(84)90282-1 |
0.508 |
|
1984 |
Gonzalez-Barcena D, Mendoza F, Medina R, Coy DH, Murphy WA, Schally AV. Effect of Ala-2-D-Trp-8-D-Cys-14-somatostatin on the arginine induced release of insulin, GH and glucagon in normal men. Endocrine Research. 10: 39-48. PMID 6146518 DOI: 10.1080/07435808409046764 |
0.397 |
|
1984 |
Gero TW, Spatola AF, Torres-Aleman I, Schally AV. Synthesis and biological activity of a cyclic pseudohexapeptide analog of somatostatin Biochemical and Biophysical Research Communications. 120: 840-845. PMID 6145411 DOI: 10.1016/S0006-291X(84)80183-7 |
0.583 |
|
1984 |
Schally AV, Comaru-Schally AM, Redding TW. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 175: 259-81. PMID 6141569 DOI: 10.3181/00379727-175-41797 |
0.404 |
|
1984 |
Redding TW, Schally AV. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proceedings of the National Academy of Sciences of the United States of America. 81: 248-52. PMID 6141560 DOI: 10.1073/PNAS.81.1.248 |
0.311 |
|
1984 |
Torres-Aleman I, Mason-Garcia M, Schally AV. Stimulation of insulin secretion by corticotropin-releasing factor (CRF) in anesthetized rats. Peptides. 5: 541-6. PMID 6089146 DOI: 10.1016/0196-9781(84)90084-6 |
0.599 |
|
1983 |
Merchenthaler I, Vigh S, Petrusz P, Schally AV. Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. The American Journal of Anatomy. 165: 385-96. PMID 6760710 DOI: 10.1002/Aja.1001650404 |
0.328 |
|
1983 |
Vécsei L, Bollók I, Telegdy G, Coy DH, Schally AV. Effect of intracerebroventricular administration of beta-/Tyr9/-melanotropin-/9-18/ on rotational behavior induced by substantia nigra lesion in rats. Neuropeptides. 3: 435-42. PMID 6664471 DOI: 10.1016/0143-4179(83)90034-3 |
0.348 |
|
1983 |
Liposits Z, Görcs T, Sétáló G, Lengvári I, Flerkó B, Vigh S, Schally AV. Ultrastructural characteristics of immunolabelled, corticotropin releasing factor (CRF)-synthesizing neurons in the rat brain. Cell and Tissue Research. 229: 191-6. PMID 6600971 DOI: 10.1007/Bf00217891 |
0.36 |
|
1983 |
Debeljuk L, Maines VM, Coy DH, Schally AV. Effect of a powerful antagonist of LH-RH on testicular function in prepubertal male rats. Archives of Andrology. 11: 89-93. PMID 6414396 DOI: 10.3109/01485018308987466 |
0.408 |
|
1983 |
Mills TM, Copland JA, Coy DH, Schally AV. Is the postovulatory release of follicle-stimulating hormone in the rabbit mediated by luteinizing hormone-releasing hormone? Endocrinology. 113: 1020-4. PMID 6409590 DOI: 10.1210/ENDO-113-3-1020 |
0.411 |
|
1983 |
Asch RH, Balmaceda JP, Borghi MR, Niesvisky R, Coy DH, Schally AV. Suppression of the positive feedback of estradiol benzoate on gonadotropin secretion by an inhibitory analog of luteinizing hormone-releasing hormone (LRH) in oophorectomized rhesus monkeys: evidence for a necessary synergism between LRH and estrogens. The Journal of Clinical Endocrinology and Metabolism. 57: 367-72. PMID 6408113 DOI: 10.1210/JCEM-57-2-367 |
0.335 |
|
1983 |
Torres-Aleman I, Vigh S, Merchenthaler I, Somogyvari-Vigh A, Carter WH, Schally AV. Radioimmunoassay of CRF-like material in rat plasma: validation of the method. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 173: 355-61. PMID 6306675 DOI: 10.3181/00379727-173-41656 |
0.588 |
|
1983 |
Hierowski MT, Perla A, Redding TW, Schally AV. The presence of LHRH-like receptors in Dunning R3327H prostate tumors. Febs Letters. 154: 92-96. PMID 6299799 DOI: 10.1016/0014-5793(83)80881-3 |
0.325 |
|
1983 |
Redding TW, Schally AV. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 80: 1459-62. PMID 6219395 DOI: 10.1073/PNAS.80.5.1459 |
0.352 |
|
1983 |
de Quijada MG, Redding TW, Coy DH, Torres-Aleman I, Schally AV. Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin. Proceedings of the National Academy of Sciences of the United States of America. 80: 3485-8. PMID 6134284 DOI: 10.1073/Pnas.80.11.3485 |
0.64 |
|
1983 |
Redding TW, Schally AV. Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones. Proceedings of the National Academy of Sciences of the United States of America. 80: 1078-82. PMID 6133278 DOI: 10.1073/PNAS.80.4.1078 |
0.366 |
|
1982 |
Konturek SJ, Meyers CA, Kwiecień N, Obtulowicz W, Tasler J, Oleksy J, Kopp B, Coy DH, Schally AV. Effect of human pancreatic polypeptide and its c-terminal hexapeptide on pancreatic secretion in man and in the dog Scandinavian Journal of Gastroenterology. 17: 395-399. PMID 7134866 DOI: 10.3109/00365528209182074 |
0.304 |
|
1982 |
Telegdy G, Vécsei L, Schally AV, Coy DH. The interaction between beta-[Tyr9]melanotropin-(9-18), haloperidol and amphetamine in different behavior tests of rats. Pharmacology, Biochemistry, and Behavior. 17: 15-8. PMID 7122660 DOI: 10.1016/0091-3057(82)90255-6 |
0.302 |
|
1982 |
Zarate A, Canales ES, Sthory I, Coy DH, Comaru-Schally AM, Schally AV. Anovulatory effect of a LHRH antagonist in women. Contraception. 24: 315-20. PMID 7030615 DOI: 10.1016/0010-7824(81)90044-5 |
0.336 |
|
1982 |
Balmaceda JP, Schally AV, Coy D, Asch RH. The effects of an LH-RH antagonist ([N-Ac-D-Trp(1)(3), D-p-Cl-Phe(2), D-Phe(6), D-Ala(10)]-LH-RH) during the preovulatory period of the rhesus monkey. Contraception. 24: 275-81. PMID 7030613 DOI: 10.1016/0010-7824(81)90040-8 |
0.349 |
|
1982 |
Schally AV, Chang RC, Arimura A, Redding TW, Fishback JB, Vigh S. High molecular weight peptide with corticotropin-releasing factor activity from porcine hypothalami. Proceedings of the National Academy of Sciences of the United States of America. 78: 5197-201. PMID 6975479 DOI: 10.1073/PNAS.78.8.5197 |
0.362 |
|
1982 |
Schally AV, Arimura A, Coy DH. Recent approaches to fertility control based on derivative of LH-RH. Vitamins and Hormones. 38: 257-323. PMID 6814060 DOI: 10.1016/S0083-6729(08)60487-2 |
0.47 |
|
1982 |
Konturek SJ, Tasler J, Jaworek J, Dobrzańska M, Coy DH, Schally AV. Comparison of TRH and anorexigenic peptide on food intake and gastrointestinal secretions. Peptides. 235-40. PMID 6806786 DOI: 10.1016/0196-9781(81)90037-1 |
0.375 |
|
1982 |
Redding TW, Coy DH, Schally AV. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 79: 1273-6. PMID 6803239 DOI: 10.1073/PNAS.79.4.1273 |
0.341 |
|
1982 |
Coy DH, Horvath A, Nekola MV, Coy EJ, Erchegyi J, Schally AV. Peptide antagonists of LH-RH: large increases in antiovulatory activities produced by basic D-amino acids in the six position. Endocrinology. 110: 1445-7. PMID 6800774 DOI: 10.1210/Endo-110-4-1445 |
0.311 |
|
1982 |
Konturek SJ, Jaworek J, Cieszkowski M, Schally AV. Effect of thyrotropin-releasing hormone on gastro-intestinal secretions in dogs. Life Sciences. 29: 2289-98. PMID 6798347 DOI: 10.1016/0024-3205(81)90562-2 |
0.432 |
|
1982 |
Vigh S, Merchenthaler I, Torres-Aleman I, Sueiras-Diaz J, Coy DH, Carter WH, Petrusz P, Schally AV. Corticotropin releasing factor (CRF): immunocytochemical localization and radioimmunoassay (RIA). Life Sciences. 31: 2441-8. PMID 6759831 DOI: 10.1016/0024-3205(82)90748-2 |
0.601 |
|
1982 |
Nekola MB, Horvath A, Ge LJ, Coy DH, Schally AV. Suppression of ovulation in the rat by an orally active antagonist of luteinizing hormone-releasing hormone. Science (New York, N.Y.). 218: 160-2. PMID 6750790 DOI: 10.1126/SCIENCE.6750790 |
0.428 |
|
1982 |
Sundaram K, Connell KG, Bardin CW, Samojlik E, Schally AV. Inhibition of pituitary-testicular function with [D-Trp6] luteinizing hormone-releasing hormone in rhesus monkeys. Endocrinology. 110: 1308-14. PMID 6460610 DOI: 10.1210/ENDO-110-4-1308 |
0.33 |
|
1982 |
Redding TW, Schally AV. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 78: 6509-12. PMID 6458815 DOI: 10.1073/PNAS.78.10.6509 |
0.371 |
|
1982 |
Sueiras-Diaz J, Coy DH, Vigh S, Redding TW, Huang WY, Torres-Aleman I, Schally AV. Synthesis and biological properties of ovine corticotropin-releasing factor (CRF). Life Sciences. 31: 429-35. PMID 6290814 DOI: 10.1016/0024-3205(82)90327-7 |
0.643 |
|
1982 |
Giguère V, Labrie F, Côté J, Coy DH, Sueiras-Diaz J, Schally AV. Stimulation of cyclic AMP accumulation and corticotropin release by synthetic ovine corticotropin-releasing factor in rat anterior pituitary cells: site of glucocorticoid action. Proceedings of the National Academy of Sciences of the United States of America. 79: 3466-9. PMID 6285350 DOI: 10.1073/Pnas.79.11.3466 |
0.368 |
|
1982 |
Labrie F, Veilleux R, Lefevre G, Coy DH, Sueiras-Diaz J, Schally AV. Corticotropin-releasing factor stimulates accumulation of adenosine 3', 5'-monophosphate in rat pituitary corticotrophs. Science (New York, N.Y.). 216: 1007-8. PMID 6281886 DOI: 10.1126/Science.6281886 |
0.375 |
|
1982 |
Schwarzstein L, Aparicio NJ, Schally AV. D-Tryptophan-6-luteinizing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia. International Journal of Andrology. 5: 171-8. PMID 6213567 DOI: 10.1111/J.1365-2605.1982.Tb00244.X |
0.433 |
|
1982 |
Grossman A, Kruseman AC, Perry L, Tomlin S, Schally AV, Coy DH, Rees LH, Comaru-Schally AM, Besser GM. New hypothalamic hormone, corticotropin-releasing factor, specifically stimulates the release of adrenocorticotropic hormone and cortisol in man. Lancet (London, England). 1: 921-2. PMID 6122767 DOI: 10.1016/S0140-6736(82)91929-8 |
0.51 |
|
1981 |
Erchegyi J, Coy DH, Nekola MV, Coy EJ, Schally AV, Mezo I, Teplan I. Luteinizing hormone-releasing hormone analogs with increased anti-ovulatory activity. Biochemical and Biophysical Research Communications. 100: 915-20. PMID 7023483 DOI: 10.1016/0006-291X(81)91910-0 |
0.347 |
|
1981 |
Ehrensing RH, Kastin AJ, Schally AV. Behavioral and hormonal effects of prolonged high doses of LHRH in male impotency. Peptides. 2: 115-21. PMID 7022397 DOI: 10.1016/0196-9781(81)90065-6 |
0.504 |
|
1981 |
Crim LW, Evans DM, Coy DH, Schally Av. Control of gonadotrophic hormone release in trout: influence of synthetic LH-RH and LH-RH analogues in vivo and in vitro. Life Sciences. 28: 129-35. PMID 7019610 DOI: 10.1016/0024-3205(81)90544-0 |
0.394 |
|
1981 |
Debeljuk L, Rettori V, Goijman S, Coy DH, Schally AV. Effect of cycloheximide on the LH release induced by a superactive analog of LH-RH. Archives of Andrology. 5: 345-8. PMID 7004364 DOI: 10.3109/01485018008987004 |
0.518 |
|
1981 |
Asch RH, Balmaceda JP, Eddy CA, Siler-Khodr T, Coy DH, Schally AV. Inhibition of the postcastration rise of luteinizing hormone and follicle-stimulating hormone in female rhesus monkeys (Macaca mulatta) by the administration of a luteinizing hormone-releasing hormone inhibitory analog ([N-Ac-D-Trp1-3,D-p-Cl-phe2,D-Phe6,D-Ala10]-LH-RH). Fertility and Sterility. 36: 388-91. PMID 6793405 DOI: 10.1016/S0015-0282(16)45742-0 |
0.444 |
|
1981 |
Garcia-Centenera JA, Vilchez-Lafuente JM, Hervas F, Alba JP, Pozuelo V, Coy DH, Schally AV. Thyrotrophin and prolactin response to beta-(pyrazolyl-1)-alanine-2-TRH in normal males. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 13: 107-9. PMID 6785179 DOI: 10.1055/s-2007-1019186 |
0.322 |
|
1981 |
Debeljuk L, Rettori V, Goijman S, Coy DH, Schally AV. Effects of a superactive analogue of LH-RH on the hypothalamo-pituitary-testicular axis in male rats pretreated with estrogens. Archives of Andrology. 6: 39-46. PMID 6782960 DOI: 10.3109/01485018108987344 |
0.429 |
|
1981 |
Laron Z, Dickerman Z, Ben Zeev Z, Prager-Lewin R, Comaru-Schally AM, Schally AV. Long-term effect of D-Trp6-luteinizing hormone-releasing hormone on testicular size and luteinizing hormone, follicle-stimulating hormone, and testosterone levels in hypothalamic hypogonadotropic males. Fertility and Sterility. 35: 328-31. PMID 6781940 DOI: 10.1016/S0015-0282(16)45381-1 |
0.485 |
|
1981 |
Chang RC, Huang WY, Redding TW, Arimura A, Coy DH, Schally AV. Isolation and structure of several peptides from porcine hypothalami. Biochimica Et Biophysica Acta. 625: 266-73. PMID 6776995 DOI: 10.1016/0005-2795(80)90290-1 |
0.347 |
|
1981 |
Tolis G, Mehta A, Comaru-Schally AM, Schally AV. Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man. The Journal of Clinical Investigation. 68: 819-22. PMID 6456277 DOI: 10.1172/JCI110320 |
0.399 |
|
1981 |
Asch RH, Siler-Khodr TM, Smith CG, Schally AV. Luteolytic effect of D-Trp6-luteinizing hormone-releasing hormone in the rhesus monkey (Macaca mulatta). The Journal of Clinical Endocrinology and Metabolism. 52: 565-71. PMID 6450776 DOI: 10.1210/JCEM-52-3-565 |
0.317 |
|
1981 |
Chang RC, Huang WY, Arimura A, Redding TW, Coy DH, Saffran M, Kong A, Hamilton JW, Cohn DV, Schally AV. Isolation, structure and synthesis of a heptapeptide with in vitro ACTH-releasing activity from porcine hypothalamus. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Mã©Tabolisme. 13: 228-32. PMID 6263778 DOI: 10.1055/s-2007-1019228 |
0.587 |
|
1981 |
Nekola MV, Pedroza E, Schally AV. Paradoxical effects of D-Trp6-LHRH in immature female rats correlated with changes in ACTH, prolactin, and corticosterone levels. Biology of Reproduction. 24: 505-11. PMID 6263374 DOI: 10.1095/Biolreprod24.3.505 |
0.374 |
|
1981 |
Laron Z, Zeev Z, Kauli R, Comaru-Schally A, Schally AV. D-Trp6-Analogue Of Luteinising Hormone Releasing Hormone In Combination With Cyproterone Acetate To Treat Precocious Puberty The Lancet. 318: 955-956. PMID 6117727 DOI: 10.1016/S0140-6736(81)91155-7 |
0.477 |
|
1981 |
Hierowski MT, Waring AJ, Schally AV. Synthesis and degradation of cyclic nucleotides in the pituitary gland, ovary and testis of rats treated with D-Trp6-luteinizing hormone-releasing hormone. Biochimica Et Biophysica Acta. 675: 232-8. PMID 6115676 DOI: 10.1016/0304-4165(81)90232-4 |
0.495 |
|
1981 |
Kewley CF, Millar RP, Berman MC, Schally AV. Depolarization- and ionophore-induced release of octacosa somatostatin from stalk median eminence synaptosomes. Science (New York, N.Y.). 213: 913-5. PMID 6114560 DOI: 10.1126/SCIENCE.6114560 |
0.327 |
|
1981 |
Meyers CA, Kastin AJ, Schally AV, Coy DH. Use of the mouse vas deferens assay to evaluate the action of somatostatin peptides on gastric acid secretion. Digestion. 21: 21-4. PMID 6112182 DOI: 10.1159/000198515 |
0.521 |
|
1981 |
Schally AV, Coy DH, Arimura A. LH-RH agonists and antagonists. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 18: 318-24. PMID 6110575 DOI: 10.1002/J.1879-3479.1980.Tb00507.X |
0.442 |
|
1981 |
Rodriguez-Arnao MD, Rainbow SJ, Comaru-Schally AM, Meyers CA, Gomez-Pan A, Woodhead S, Schally AV, Coy DH, Hall R. EFFECTS OF PROSOMATOSTATIN ON GROWTH HORMONE AND PROLACTIN RESPONSE TO ARGININE IN MAN Comparison with Somatostatin The Lancet. 317: 353-356. PMID 6109991 DOI: 10.1016/S0140-6736(81)91673-1 |
0.48 |
|
1981 |
Meyers CA, Murphy WA, Redding TW, Coy DH, Schally AV. Synthesis and biological actions of prosomatostatin. Proceedings of the National Academy of Sciences of the United States of America. 77: 6171-4. PMID 6108563 DOI: 10.1073/PNAS.77.10.6171 |
0.368 |
|
1980 |
Chey WY, Coy DH, Konturek SJ, Schally AV, Tasler J. Enkephalin inhibits the release and action of secretin on pancreatic secretion in the dog. The Journal of Physiology. 298: 429-36. PMID 7359425 DOI: 10.1113/jphysiol.1980.sp013092 |
0.347 |
|
1980 |
Kastin AJ, Mauk MD, Schally AV, Coy DH. Unusual dose-related effect of an endorphin analog in a complex maze. Physiology & Behavior. 25: 959-62. PMID 7220637 DOI: 10.1016/0031-9384(80)90317-0 |
0.478 |
|
1980 |
Kastin AJ, Coy DH, Schally AV, Zadina JE. Dissociation of effects of LH-RH analogs on pituitary regulation and reproductive behavior. Pharmacology, Biochemistry, and Behavior. 13: 913-4. PMID 7010384 DOI: 10.1016/0091-3057(80)90228-2 |
0.59 |
|
1980 |
Meyers CA, Coy DH, Murphy WA, Redding TW, Arimura A, Schally AV. [Phe4]somatostatin: a potent, selective inhibitor of growth hormone release. Proceedings of the National Academy of Sciences of the United States of America. 77: 577-9. PMID 6987657 DOI: 10.1073/pnas.77.1.577 |
0.393 |
|
1980 |
Kastin AJ, Zadina JE, Schally AV. Foundations of the clinical use of LHRH: early studies with the porcine hypothalamic hormone. Materia Medica Polona. Polish Journal of Medicine and Pharmacy. 12: 33-6. PMID 6799707 |
0.446 |
|
1980 |
Vilchez-Martinez JA, Pedroza E, Arimura A, Schally AV. Biphasic fluctuation of pituitary responsiveness to LH-RH during the rat estrous cycle. Role of endogenous LH-RH and ovarian steroids in its modulation. Neuroendocrinology. 31: 73-80. PMID 6771667 DOI: 10.1159/000191160 |
0.341 |
|
1980 |
Schally AV, Chang RC, Huang WY, Coy DH, Kastin AJ, Redding TW. Isolation, structure, biological characterization, and synthesis of beta-[Tyr9]melanotropin-(9-18) decapeptide from pig hypothalami. Proceedings of the National Academy of Sciences of the United States of America. 77: 3947-51. PMID 6254004 DOI: 10.1073/Pnas.77.7.3947 |
0.355 |
|
1980 |
Pedroza E, Vilchez-Martinez JA, Coy DH, Arimura A, Schally AV. Reduction of LH-RH pituitary and estradiol uterine binding sites by a superactive analog of luteinizing hormone-releasing hormone. Biochemical and Biophysical Research Communications. 95: 1056-62. PMID 6251826 DOI: 10.1016/0006-291X(80)91580-6 |
0.376 |
|
1980 |
Kastin AJ, Arimura A, Gonzalez-Barcena D, Fishback J, Schally AV, Coy DH. Dynamics of injected somatostatin in blood of patients with hepatic failure and acromegaly. Peptides. 1: 257-9. PMID 6112735 DOI: 10.1016/0196-9781(80)90063-7 |
0.33 |
|
1980 |
Kastin AJ, Nissen C, Zadina JE, Schally AV, Ehrensing RH. Naloxone-like actions of MIF-1 do not require the presence of the pituitary. Pharmacology, Biochemistry, and Behavior. 13: 907-12. PMID 6111087 DOI: 10.1016/0091-3057(80)90227-0 |
0.405 |
|
1980 |
Kastin AJ, Kostrzewa RM, Schally AV, Coy DH. Neonatal administration of Met-enkephalin facilitates maze performance of adult rats. Pharmacology, Biochemistry, and Behavior. 13: 883-6. PMID 6111085 DOI: 10.1016/0091-3057(80)90223-3 |
0.478 |
|
1980 |
Canales ES, Montvelinsky H, Fonseca ME, Zárate A, Kastin AJ, Coy DH, Schally AV. The use of a potent stimulatory LHRH analog (D-Trp-6, LHRH) in the induction of ovulation. International Journal of Fertility. 25: 193-7. PMID 6108929 |
0.412 |
|
1980 |
Canales ES, Montvelinsky H, Zárate A, Kastin AJ, Coy DH, Schally AV. Suppressive effect of an inhibitory LHRH analog on the gonadotropin response to LHRH in normal women. International Journal of Fertility. 25: 190-2. PMID 6108928 |
0.507 |
|
1980 |
González-Bárcena D, Ortíz HT, Gordon F, Kastin AJ, Coy D, Schally AV. Influence of LH-RH agonists and antagonists on gonadotropin release in humans. International Journal of Fertility. 25: 185-9. PMID 6108927 |
0.512 |
|
1980 |
Schally AV, Huang WY, Chang RC, Arimura A, Redding TW, Millar RP, Hunkapiller MW, Hood LE. Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus Proceedings of the National Academy of Sciences of the United States of America. 77: 4489-4493. PMID 6107906 DOI: 10.1073/PNAS.77.8.4489 |
0.306 |
|
1980 |
Kastin AJ, Schally AV, Kostrzewa RM. Possible aminergic mediation of MSH release and of the CNS effects of MSH and MIF-I. Federation Proceedings. 39: 2931-6. PMID 6105977 |
0.533 |
|
1980 |
Hanker JP, Knippenberg J, Kastin AJ, Wickings EJ, Schally AV, Coy DH, Schneider HP. Gonadotropin release during repeated administration of d-Leu6 des Gly10-LH-RH-EA at different stages of the menstrual cycle and in functional amenorrhea. International Journal of Fertility. 25: 7-17. PMID 6104647 |
0.557 |
|
1980 |
Chihara K, Arimura A, Kubli-Garfias C, Schally AV. Enhancement of immunoreactive somatostatin release into hypophysial portal blood by electrical stimulation of the preoptic area in the rat. Endocrinology. 105: 1416-8. PMID 499080 DOI: 10.1210/Endo-105-6-1416 |
0.386 |
|
1980 |
Arimura A, Serafini P, Talbot S, Schally AV. Reduction of testicular luteinizing hormone/human chorionic gonadotropin receptors by [D-Trp6]-luteinizing hormone releasing hormone in hypophysectomized rats. Biochemical and Biophysical Research Communications. 90: 687-93. PMID 228668 DOI: 10.1016/0006-291X(79)91882-5 |
0.416 |
|
Show low-probability matches. |